UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 10-K

(Mark One)
þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended December 31, 2007
or
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from          to

Commission file number 000-23092

NATIONAL DENTEX CORPORATION

(Exact name of registrant as specified in its charter)

MASSACHUSETTS	04-2762050
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
2 Vision Drive,	01760
Natick, MA	(Zip Code)
(Address of Principal Executive Offices)

(508) 907-7800
(Registrant’s Telephone No., including Area Code)
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Exchange on Which Registered
Common Stock, par value $.01 per share	The NASDAQ Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes o     No þ

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes o     No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o	Accelerated filer þ	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.  Yes o     No þ

As of June 30, 2007, the aggregate market value of the 5,409,299 outstanding shares of voting stock held by non-affiliates of the registrant was $101,532,542, based upon the closing price of the Common Stock on the NASDAQ Global Market on such date.

As of March 5, 2008, 5,584,021 shares of the registrant’s Common Stock, par value $.01 per share, were issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the proxy statement for the annual stockholders’ meeting scheduled to be held on May 13, 2008 which we plan to file with the SEC no later than 120 days after the end of our fiscal year ended December 31, 2007, are incorporated by reference into Part III.

TABLE OF CONTENTS

PART I
	Item 1. Business
	Item 1A. Risk Factors
	Item 1B. Unresolved Staff Comments
	Item 2. Properties
	Item 3. Legal Proceedings
	Item 4. Submission of Matters to a Vote of Security Holders
PART II
	Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
	Item 6. Selected Financial Data
	Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
	Item 7A. Quantitative and Qualitative Disclosures about Market Risk
	Item 8. Financial Statements and Supplementary Data
	Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
	Item 9A. Controls and Procedures
	Item 9A(T). Controls and Procedures
	Item 9B. Other Information
PART III
	Item 10. Directors, Executive Officers and Corporate Governance
	Item 11. Executive Compensation
	Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters
	Item 13. Certain Relationships and Related Transactions
	Item 14. Principal Accountant Fees and Services
PART IV
	Item 15. Exhibits and Financial Statement Schedules
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED STATEMENTS OF INCOME
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS December 31, 2007
SIGNATURES
EXHIBIT INDEX
EX-10.25 Written Summary of Non-Employee Director Compensation Arrangements
EX-23 Consent of PricewaterhouseCoopers LLP
EX-31.1 Section 302 Certification of CEO
EX-31.2 Section 302 Certification of CFO
EX-32.1 Section 906 Certification of CEO
EX-32.2 Section 906 Certification of CFO

PART I

Item 1.   Business

General

We were founded in 1982 as H&M Laboratories Services, Inc., a Massachusetts corporation, which acquired six full-service dental laboratories and related branch laboratories from Healthco, Inc. In 1983, we changed our name to National Dentex Corporation and acquired 20 additional full-service dental laboratories and related branch laboratories from Lifemark Corporation. Our acquisition strategy is to consolidate our position within the dental laboratory industry and use our financial and operational synergies to create a competitive advantage. Over the last five years we have acquired the following stand-alone laboratory facilities: in 2003, Salem Dental, Top Quality Partials, Midtown Dental and Thoele Dental; in 2004, D.H. Baker Dental; in 2005, Wornson-Polzin Dental Laboratory and Green Dental Laboratories; and in 2006, Impact Dental and the Keller Group. Impact, located in the Canadian province of Ontario, was our first acquisition outside of the United States. Over the past five years, we also acquired various smaller laboratories that we have consolidated into our existing operations.

We currently own and operate 48 dental laboratories, consisting of 41 full-service dental laboratories and 7 branch laboratories located in 31 states throughout the United States and in one province of Canada. Our dental laboratories custom design and fabricate dentures, crowns and fixed bridges, and other dental prosthetic appliances. Each dental laboratory operates under its own business name. Our principal executive offices are located at 2 Vision Drive, Natick, MA 01760, telephone number (508) 907-7800. Our corporate web site is located at www.nationaldentex.com. We make available free of charge through our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports filed or furnished pursuant to Section 13(a) of the Securities Exchange Act of 1934 as soon as practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission. References to our website address are provided for convenience only and do not constitute, or should be viewed as, an incorporation by reference of the information contained therein. Therefore, such information should not be considered a part of this report.

Information as to Industry and Operating Segments

Our business consists of a single industry segment, which is the design, fabrication, marketing and sale of custom dental prosthetic appliances for and to dentists. We report on three reportable segments within this single industry segment. These three segments are known as Green Dental, representing the operations of Green Dental Laboratories, Inc. of Heber Springs, Arkansas which we acquired in March 2005; Keller, representing the operations of Keller Group, Incorporated with laboratories in St. Louis, Missouri and Louisville, Kentucky which we acquired in October, 2006; and NDX Laboratories, which represents our remaining laboratories, including Impact Dental Laboratory Limited, which we acquired in October, 2006. You will find information about these segments in Note 11 “Segment Information”, which you will find in Part II, Item 8 of this annual report.

Description of Business

Our dental laboratories in all three of our reportable segments design and fabricate custom dental prosthetic appliances such as dentures, crowns and bridges. These products are produced by trained technicians working in dental laboratories in accordance with work orders and cases (consisting of impressions, models and occlusal registrations of a patient’s teeth) provided by the dentist. Dentists are the direct purchasers of our products.

Our products are grouped into the following three main categories:

Restorative Products.  Restorative products that our dental laboratories sell consist primarily of crowns and bridges. A crown replaces the part of a tooth that is visible, and is usually made of gold, porcelain or zirconia. A bridge is a restoration of one or more missing teeth that is permanently attached to the natural teeth or roots. In addition to the traditional crown, we also make porcelain jackets, which are crowns constructed entirely of porcelain; onlays, which are partial crowns which do not cover all of the visible tooth; and precision crowns, which are restorations designed to receive and connect a removable partial denture. We also make inlays, which are restorations made to fit a prepared tooth cavity and then cemented into place.

1

Reconstructive Products.  Reconstructive products sold by our dental laboratories consist primarily of partial dentures and full dentures. Partial dentures are removable dental prostheses that replace missing teeth and associated structures. Full dentures are dental prostheses that substitute for the total loss of teeth and associated structures. We also sell precision attachments, which connect a crown and an artificial prosthesis, and implants, which are fixtures anchored securely in the bone of the mouth to which a crown, partial or full denture is secured by means of screws or clips.

Cosmetic Products.  Cosmetic products sold by our dental laboratories consist primarily of porcelain veneers and ceramic crowns. Porcelain veneers are thin coverings of porcelain cemented to the front of a tooth to enhance personal appearance. Ceramic crowns are crowns made from ceramic materials that most closely replicate natural teeth. We also sell composite inlays and onlays, which replace silver fillings for a more natural appearance, and orthodontic appliances, which are products fabricated to move existing teeth to enhance function and appearance.

Laboratory and Corporate Operations

Our full-service dental laboratories design and manufacture a full range of custom-made dental prosthetic appliances. These custom products are manufactured from raw materials, such as high noble, noble and predominantly base alloys, zirconia, dental resins, composites and porcelain. There are different production processes for the various types of prosthetic appliances depending upon the product and the materials used in the type of appliance being manufactured, each of which requires different skills and levels of training. Our dental laboratories perform numerous quality control checks throughout the production cycle to improve the quality of our products and to better ensure that the design and appearance satisfy the needs of the dentist and the patient. Our branch dental laboratories are smaller in size and offer a limited number of products. When a branch receives an order that it cannot fill, the branch refers the order to one of our affiliated full-service dental laboratories.

We operate each of our dental laboratories as a stand-alone facility under the direction of a local manager responsible for operation of the dental laboratory, supervision of its technical and sales staff and delivery of quality products and services. Most of our dental laboratories markets and sells its products through its own direct sales force, supported by group managers and company-wide marketing programs. Employees at each dental laboratory have a direct stake in the financial success of the dental laboratory through participation in our performance incentive plans.

Our corporate management provides our overall strategy, direction and financial management and negotiates all acquisitions. Corporate personnel also support the operations of our dental laboratories by performing functions that are not directly related to the production and sale of dental laboratory products, such as processing payroll and related benefit programs, obtaining insurance and procuring financing. Our corporate management provides marketing, financial and administrative services, negotiates national purchasing arrangements, and sets quality and performance standards for our dental laboratories. Finally, our corporate management includes industry recognized technical experts who guide and direct our investments in new technology and materials.

Sales and Marketing

The majority of our local dental laboratories market and sell their products through their own direct sales force. The sales force interacts with dentists within its market area, primarily through visits to dentists’ offices, to introduce the dental laboratory’s services and products offered, and to promote new products and techniques that can assist dentists in expanding their practices. Our dentist-focused marketing and sales program, entitled the “NDX Reliance Program”^tm is specifically designed to make choosing a dental laboratory an easier decision for dentists. Its five components — Practice Support, Laboratory Systems, Quality Assurance, Reliance Restorations and a Continuing Education Series — differentiate our qualified laboratories from their many competitors. We believe that this unique approach to assist the dentist and his or her staff to improve chairtime efficiencies while providing exceptional service, superior quality and quick and timely product delivery will enhance our ability to expand our base of business by establishing lasting professional relationships with our customers. Our laboratories currently employ a total of 42 sales representatives. In addition, our dental laboratories, alone or with local dental societies, dental schools or study clubs, sponsor technical training clinics for dentists and their staffs on topics such as advanced clinical techniques. The local dental laboratories also exhibit at state and local dental conventions.

2

Following our acquisition of Keller in 2006, we now also market more directly to the entire United States marketplace. Keller markets using a direct mail and trade advertising approach and focuses on products that can generate strong revenue growth. In addition, the exclusive product license on the NTI-tss plus^tm device, an alternative to full-coverage bite guards that is also approved by the FDA for use in the prevention of medically diagnosed migraine pain and jaw disorders, will help us to further diversify our business growth strategy.

Competition

The dental laboratory industry is highly competitive and fragmented. A typical dental laboratory’s business originates from dentists located within 50 miles of the dental laboratory. We believe there are currently approximately 12,000 dental laboratories in the United States. We estimate that our sales presently represent less than 3% of the total sales of custom-made dental prosthetic appliances in the United States. Competition is primarily from other dental laboratories in the respective local market areas. The vast majority of dental laboratories consist of single business units, although we recognize that there are several other multiple-location operators, including Dental Services Group, Dental Technologies, Inc. and NovaDent. These groups compete with us in several market areas. We also face competition from various mail order dental laboratories, most notably Glidewell Laboratories.

The domestic industry has experienced growing competition from low wage countries, particularly from laboratories manufacturing in China. Competition for business in the low-price segment of the marketplace intensified in 2006 and has continued in 2007. Dental laboratories manufacturing in China, including Dentsply-Prident, Dentalle and Exceldent, operate large, modern facilities. In addition to partnering with laboratories in the United States, some have also reached agreements to provide laboratory services for some of the larger, price focused, economy dental practice chains. In addition, the number of smaller domestic competitors that seek to take advantage of these low wage economies and compete primarily using price as the main differentiator has continued to grow. We continue to evaluate such competitive threats as well as our own growth opportunities arising from globalization and changing marketplaces to ensure we continue to provide the products and services required by our clients at competitive prices.

Our ability to produce quality products locally, to deliver such products on a timely basis, to provide convenience for the dentist through the breadth of our product line, to provide technical assistance, and our sponsorship of educational clinics, all provide us with what we consider to be a competitive advantage over other dental laboratories in the local markets in which our dental laboratories operate. Most dentists use a limited number of dental laboratories. We believe they prefer and tend to rely on those laboratories which produce quality products delivered on a timely basis and which carry all of the products which they may need, even if a particular item is a newer specialty product used only sporadically by the dentist. While price is one of the competitive factors in the dental laboratory industry, we believe that most dentists consider product quality and consistency, service, and breadth of product line to also be important factors in selecting dental laboratories. We believe that we compete favorably with respect to all of these factors. Our ability to provide newer specialty products for implantology, adult orthodontics and cosmetic dentistry, which require highly skilled technicians, more extensive inventories, additional working capital, and investment in both training and capital equipment, also distinguishes us from the many other dental laboratories which do not have comparable resources to provide these products. While such specialty products presently represent less than 20% of our business, we believe that the ability to offer these products will become increasingly essential for dental laboratories to remain competitive. Additionally, our ability to offer computer-assisted design and computer-assisted manufacturing (“CAD-CAM”) fabricated, metal-free restorations through our own centralized milling centers allows us to participate fully in this fast growing segment.

Employees

As of December 31, 2007, we had 2,027 employees, 1,974 of whom worked at individual laboratories. Corporate management and administrative staff totaled 53 people. None of our employees are covered by a collective bargaining agreement. Management considers our employee relations to be good.

3

Intellectual Property

Our general technological know-how, experience and workforce are important to the conduct of our business. Each of our dental laboratories operates under its own trade name, and we consider these trade names to be materially important to the conduct of our business. Also important is the development and maintenance of customer relationships. We expect that our continued focus on ensuring our clients get a consistent product that is delivered on time and meets or exceeds their quality expectations, will continue to assist us in generating and maintaining customer relationships and the goodwill of our dental laboratories. Finally, while we have several trademarks and licenses to use trademarks, we do not deem these to be material to the overall conduct of our business.

Backlog

Due to the individualized and customized nature of most dental products and a typical turnaround product cycle of less than seven days, there was no significant backlog of orders existing at December 31, 2007 and 2006.

Item 1A.   Risk Factors

Our business is subject to certain risks that could materially affect our financial condition, results of operations, and the value of our common stock. These risks include, but are not limited to, the ones described below. Additional risks and uncertainties that we are unaware of, or that we may currently deem immaterial, may become important factors that harm our business, financial condition, results of operations, or the value of our common stock.

Our success depends on economic and other external factors that affect consumer decisions about whether and when to have dental procedures performed.

Our business success depends in large measure on consumer decisions to have dental procedures performed. In this respect, demand for our products and our business results are sensitive to external factors that, directly or indirectly, affect consumer confidence, affect levels of disposable consumer income, or otherwise lead consumers to defer or elect not to have dental procedures performed. Examples of such external factors include the timing, duration and effects of adverse changes in overall economic conditions, including rates of job loss or growth, rising energy prices, tightening consumer credit, and increases in medical and dental costs, nationally or regionally in the markets we serve. Trends in the dental industry towards managed care may also result in decreased consumer access to dental services and thereby adversely affect demand for our products and our sales and profitability. The precise impact of these external factors is difficult to predict in advance, but one or more of these factors could adversely affect our business to the extent they adversely affect consumer spending on dental procedures.

We operate in a highly competitive and fragmented market that is increasingly global in scope.

The dental laboratory industry is highly competitive and fragmented. We believe there are currently approximately 12,000 dental laboratories in the United States. We estimate that our sales presently represent less than 3% of the total sales of custom-made dental prosthetic appliances in the United States. Competition is primarily from other dental laboratories in the respective local market areas. The vast majority of dental laboratories consist of single business units, although there are several other multiple-location operators, including Dental Services Group, Dental Technologies, Inc., and NovaDent. These groups compete with us in several market areas. We also face competition from various mail order dental laboratories, most notably Glidewell Laboratories. Our success thus depends on our ability to be competitive against many different competitors in each market area we serve. If we fail to anticipate evolving technological innovations and product offerings from our competitors, particularly offerings that seek to leverage lower labor costs available in foreign countries, or fail to offer products that appeal to the changing needs and preferences of our customers in the various markets we serve, demand for our products could decline and our operating results would be adversely affected. While the competitive importance of product quality, price, service and innovation varies from product to product, price is a factor, and we experience pricing pressures from competitors in our markets.

4

We face increased competitive pressures from larger competitors, foreign-sourced products and technology-based solutions.

The industry in which we operate continues to change and evolve. Increasing competitive pressures from offshore laboratories based in China, India and elsewhere are impacting sales growth and selling prices of certain core products, particularly partial frames and traditional crowns. Technology-based dental laboratory CAD-CAM solutions have required us to make additional investments in capital equipment. While we expect these capital investments to continue to benefit our operations in future periods, there is no assurance that they will be able to do so. Certain of these technology-based solutions also enable dentists to fabricate restorations in their offices rather than purchasing them from an off-site laboratory.

Moreover, the dental laboratory industry has continued to consolidate and is increasingly drawing the attention of private equity investors. While the consequences of these changes in the dental laboratory industry are not yet fully known, these competitors may now have greater financial and other resources than previously available to them, which could increase competitive pressures on our operations. These developments could impact the availability of suitable acquisition candidates or otherwise increase the costs of acquiring dental laboratories.

Price pressures from such new sources of competition could erode our margins and cause our financial results of operations to suffer. Our success depends on our ability to evaluate and respond to the threats arising from growing foreign competition, changing marketplaces and new technology and our ability to identify ways in which we can competitively provide the products and services demanded by our customers.

We may face increased regulatory action by, among other governmental entities, the United States Food and Drug Administration (the “FDA”).

During 2007, the industry has faced increased scrutiny from the FDA and other governmental entities concerning the safety and efficacy of dental products distributed in the United States from both foreign and domestic laboratories. As a result of the scrutiny, the FDA may propose possible registration, certification, material content and point of origin disclosure. Potential changes in laws, regulations and standards involving these issues, while new and evolving, are creating uncertainty in compliance requirements and could result in higher costs in order to comply with any revisions or additions to them.

Risks associated with our strategic acquisitions could adversely affect our business.

We have completed a number of acquisitions in recent years. Our acquisition strategy depends on our ability to identify laboratories that are suitable acquisition candidates, successfully negotiate and enter into transactions on acceptable terms, and our capacity to integrate and successfully operate newly acquired as well as our previously acquired laboratories. If we fail to locate suitable acquisition candidates, reach mistaken conclusions as to the suitability of laboratories as acquisition candidates, enter into transactions on terms that prove unfavorable to us, or fail to integrate new laboratories following an acquisition, our ability to operate and grow our business in the ways we would like could be materially and adversely effected. While we will continue to consider acquisitions as a means of enhancing shareowner value, acquisitions involve risks and uncertainties, including:

•  difficulties integrating the acquired company, retaining the acquired laboratories’ customers, and achieving the expected benefits of the acquisition, such as revenue increases, cost savings, and increases in geographic or product presence, in the desired time frames, if at all;

•  loss of key employees from the acquired company;

•  implementing and maintaining consistent standards, controls, procedures, policies and information systems; and

•  diversion of management’s attention from other business concerns.

Future acquisitions could cause us to incur additional debt, contingent liabilities, increased interest expense and higher amortization expense related to intangible assets, as well as experience dilution in earnings per share. Impairment losses on goodwill and intangible assets with an indefinite life, or restructuring charges, could also occur as a result of acquisitions.

5

If we fail to develop new or expand existing customer relationships, our ability to grow our business will be impaired.

Our growth depends on our ability to develop new customer relationships with dentists, maintain existing relationships, and to expand existing relationships with our current customers. We cannot guarantee that new customers will be found, that any such new relationships will be successful when they are in place, or that business with current customers will increase. Failure to develop and expand such relationships could have a material adverse effect on our business, results of operations and financial condition.

If we cannot continue to respond to technical innovations we may not be able to compete effectively.

We believe that our future success will depend, in part, upon our ability to continue to respond to technological innovations by the dental industry and introduce innovative design extensions for our existing products and to manufacture and market new products. We cannot assure you that we will be successful in the introduction, manufacturing and marketing of any new products or product innovations, or develop and introduce, in a timely manner, innovations to our existing products that satisfy our dentist customers’ needs or achieve market acceptance. Our failure to introduce new products successfully and in a timely manner, and at favorable margins, could harm our ability to successfully grow our business and could have a material adverse effect on our business, results of operations and financial condition.

Our failure to attract and retain qualified personnel would adversely affect our business.

Our success depends in part on the efforts and abilities of our senior management team and key employees, a number of which are approaching retirement age. Their skills, experience and industry contacts significantly benefit our operations and administration. The failure to attract, retain, and properly motivate the members of our senior management team and key employees, or to find suitable replacements for them in the event of death, ill health, resignation, or retirement, could have a negative effect on our operating results.

Our business results are adversely affected by increases in labor, benefits and related costs.

The costs of medical and other benefits have increased in recent years. The increased usage of medical benefits has intensified medical inflation in the United States. If such trends continue, then our business could be negatively affected. Changes in law that may increase the funding of, and the expense reflected for, employee benefits, could also adversely affect our financial results of operations, financial position, and competitiveness.

Our operating results can be adversely affected by changes in the cost or availability of raw materials, particularly precious metals like gold, platinum and palladium.

Pricing and availability of raw materials for use in our businesses — most especially precious metals, like gold, platinum and palladium which are components of many dental alloys — can be volatile due to numerous factors beyond our control, including domestic and international economic and geopolitical conditions, production levels, competition, consumer demand, and investor speculation. This volatility can significantly affect the availability and cost of raw materials for us, and may, therefore, have a material adverse effect on our business, results of operations and financial condition. During periods of rising prices of raw materials, there can be no assurance that we will be able to pass any portion of such increases on to customers. Prolonged higher metal costs may thus have a negative impact on gross profit percentages. Conversely, when raw material prices decline, customer demands for lower prices could result in lower sale prices and, to the extent we have existing inventory, lower margins. As a result, fluctuations in raw material prices could have a material adverse effect on our business, results of operations and financial condition. The combination of higher precious metal prices and increasing offshore competition has made it more difficult for us to pass on these additional costs without impacting our customer base.

6

Our failure to generate sufficient cash to meet our liquidity needs may affect our ability to service our indebtedness and grow our business.

Our ability to make payments on and to refinance our indebtedness, principally the amounts borrowed under our senior credit facility, and to fund planned capital expenditures and expansion efforts and strategic acquisitions we may make in the future, if any, will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive and other factors that are beyond our control.

Based on our current level of operations, we believe our cash flow from operations, together with available cash and available borrowings under our senior credit facility, will be adequate to meet future liquidity needs for at least the next twelve months. However, we cannot assure you that our business will generate sufficient cash flow from operations in the future, that our currently anticipated growth in revenues and cash flow will be realized on schedule or that future borrowings will be available to us under the senior credit facility in an amount sufficient to enable us to service indebtedness, undertake strategic acquisitions to grow our business, or to fund other liquidity needs. If we need to refinance all or a portion of our indebtedness, we cannot assure you that we will be able to do so on commercially reasonable terms or at all. The amounts that we have borrowed under our senior credit facility have increased significantly as a result of our acquisitions of Green in 2005 and Keller in 2006. Increased borrowings have increased substantially the amount of cash that we need to generate from our operations in order to meet our principal and interest payment obligations. In the event that our financial performance were to deteriorate, it could result in higher interest rates under our senior credit facility, or a default under the facility, if we are unable to maintain compliance with the financial ratio and other covenants in the facility.

An impairment in the carrying value of goodwill or other acquired intangibles could negatively affect our operating results and net worth.

The carrying value of goodwill represents the fair value of acquired businesses in excess of identifiable assets and liabilities as of the acquisition date. The carrying value of other intangibles represents the fair value of trade names and other acquired intangibles as of the acquisition date. Goodwill and other acquired intangibles expected to contribute indefinitely to our cash flows are not amortized, but must be evaluated by our management at least annually for impairment. If carrying value exceeds current undiscounted cash flows, an impairment is identified. The impairment is then measured based on the difference of fair value (discounted cash flow) and carrying value. Events and conditions that could result in impairment include changes in the industry in which we operate, as well as competition and advances in technology, or other factors leading to reduction in expected sales, profitability or cash flows. If the value of goodwill or other acquired intangibles is impaired, our earnings and net worth could be adversely affected.

Compliance with changing regulation of corporate governance, public disclosure, and accounting standards may result in additional expenses and risks.

Changing laws, regulations and standards relating to corporate governance, public disclosure and accounting practices, including the Sarbanes-Oxley Act of 2002, new Securities and Exchange Commission regulations and evolving rules applicable to publicly-traded companies on the NASDAQ Global Market, are creating uncertainty, and hence risks, for companies such as ours. These new or changed laws, regulations and standards are subject to varying interpretations due to the fact that they are new and there has not yet emerged a well-developed body of interpretation. As a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This development could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure, governance and accounting practices.

Our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased general and administrative expenses and an investment of management time and attention from revenue-generating activities to compliance activities. In particular, our efforts to comply with Section 404 of the Sarbanes-Oxley Act of 2002 and the related regulations regarding our required assessment of our internal controls over financial reporting and our external auditors’ audit of that assessment has required the commitment of significant financial and managerial resources. If our efforts to comply with new or changed laws, regulations and

7

standards differ from the activities intended by regulatory or governing bodies, we could face many material and adverse consequences, including, a possible delisting of our common stock.

Forward Looking Statements

Certain statements in this Annual Report, particularly statements contained in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate”, “believe”, “estimate”, “expect”, “plan”, “intend” and other similar expressions are intended to identify these forward-looking statements, but are not the exclusive means of identifying them. Forward-looking statements included in this Annual Report or hereafter included in other publicly available documents filed with the Securities and Exchange Commission (“SEC”), reports to our stockholders and other publicly available statements issued or released by us involve known and unknown risks, uncertainties, and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon our best estimates based upon current conditions and the most recent results of operations. We assume no obligation to update these forward-looking statements contained in this report, whether as a result of new information, future events or otherwise.

Various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, the forward-looking statements contained in this Annual Report. These include, but are not limited to, those listed above in this Item 1A, “Risk Factors.”

Item 1B.   Unresolved Staff Comments

Not applicable.

Item 2.   Properties

We currently lease a total of approximately 336,000 square feet of space. As of December 31, 2007, the future aggregate minimum rent payable for all of our leased real properties was approximately $21,190,000. We consider these properties to be modern, well maintained and suitable for our purposes and believe that our current facilities are adequate to meet our needs for the foreseeable future. We also believe that suitable substitute or replacement space is readily available at reasonable rental rates. Our principal executive and administrative offices occupy approximately 15,000 square feet of space in Natick, Massachusetts. Our 41 leased dental laboratories range in size from 1,000 to 40,000 square feet and average approximately $80,000 in annual base rent.

As of December 31, 2007, we owned seven of our dental laboratory facilities at locations in Heber Springs, Arkansas; Denver, Colorado; Metairie, Louisiana; Shreveport, Louisiana; Addison, Texas; Houston, Texas; and Waukesha, Wisconsin. These locations total approximately 150,000 square feet and range in building size from 5,000 to 41,000 square feet. We also own a building and adjacent land parcels in Jacksonville, Florida that are currently held for sale.

All of our owned real property is used in connection with our NDX Laboratories operating segment, except for our Heber Springs, Arkansas facility, which is used by our Green Dental operating segment. Our third operating segment, Keller, uses leased property located in St. Louis, Missouri and Louisville, Kentucky.

Item 3.   Legal Proceedings

We are involved from time to time in litigation incidental to our business. Our management believes that the outcome of current litigation will not have a material adverse effect upon our operations or financial condition and will not disrupt our normal operations.

In January 2005, we were served with a complaint naming us as a defendant in federal district court in a patent infringement case, PSN Illinois, LLC v. Ivoclar Vivadent, Inc. et al. The case was brought in the Eastern Division of the Northern District of Illinois. The complaint alleges that the various named defendants, including us and most

8

other major domestic dental laboratories (and some companies that supply dental laboratories), infringed a patent that was assigned to the plaintiff by using, or inducing others to use, a process for making porcelain dental veneers. The District Court judge entered summary judgment in favor of the Company and the plaintiff appealed. The appeal was heard in the Federal Circuit Court of Appeals on March 3, 2008, although it may be several months before the Federal Circuit rules on the plaintiff’s appeal. In addition, one of our suppliers has agreed to defend and indemnify us against a portion of the plaintiff’s claims, should they be upheld.

As sponsor of our 401(k) Plan, we have filed a retroactive plan amendment under the Internal Revenue Service’s Voluntary Correction Program to clarify the definition of compensation in the 401(k) Plan. Effective June 7, 2007, the Internal Revenue Service accepted the retroactive plan amendment and issued a favorable determination letter.

Item 4.   Submission of Matters to a Vote of Security Holders

No matters were submitted to a vote of our security holders during the fourth quarter of fiscal 2007.

PART II

Item 5.   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Trading Market

The NASDAQ Global Market (“Nasdaq”) is the principal market for our common stock, where our shares are traded under the symbol “NADX”. Our common stock has been publicly traded since December 21, 1993.

The following table sets forth the range of high and low sale prices for our common stock for each of the fiscal quarters of 2006 and 2007. The sale prices set forth below are based on information provided by NASDAQ.

	Price
Quarter Ending	Low		High
03/31/06	$	19.280	$	25.000
06/30/06	$	21.050	$	24.490
09/30/06	$	18.400	$	23.250
12/31/06	$	17.150	$	23.000
03/31/07	$	13.960	$	17.510
06/30/07	$	13.010	$	20.950
09/30/07	$	14.740	$	19.910
12/31/07	$	13.600	$	18.000

Holders

The approximate number of record holders of our common stock as of March 5, 2008 was 537. The number of record owners was determined from our stockholder records, and does not include beneficial owners of our common stock whose shares are held in the names of various security holders, dealers and clearing agencies. We believe that the number of beneficial owners of our common stock held by others in nominee names is approximately 1,600 beneficial holders.

Dividends

We have never paid a cash dividend on our shares of common stock and have no expectation of doing so for the foreseeable future. On December 31, 2004, we effected a three-for-two stock split in the form of a stock dividend on our common stock that was paid to stockholders of record on December 20, 2004.

9

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

In November 2002, we announced that our Board of Directors approved the repurchase by us of up to 300,000 shares of our common stock pursuant to a stock repurchase program. During the year ended December 31, 2007, we did not repurchase any shares of our common stock. We continue to consider repurchases on the open market or in privately-negotiated transactions, at management’s discretion. The following table provides information about our repurchase activity during fiscal 2007 and the number of shares that may yet be purchased under our stock repurchase program.

Issuer Purchases of Equity Securities

							Maximum Number
					Total Number of		of Shares that
					Shares Purchased		May Yet Be
	Total Number		Average		as Part of Publicly		Purchased Under
	of Shares		Price Paid		Announced Plans		the Plans or
Fiscal Period	Purchased		per Share		or Programs		Programs
January 1, 2007 - December 31, 2007		—	$	—		—		206,700

10

Stock Performance Graph

The following graph compares the cumulative total stockholder return of our common stock during the five fiscal years ended December 31, 2007 with the cumulative total return of the NASDAQ Industrial Index and a peer group index described more fully below.

This graph is not deemed to be “filed” with the SEC or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, and the graph shall not be deemed to be incorporated by reference into any prior or subsequent filings by us under the Securities Act of 1933 or the Securities Exchange Act of 1934.

COMPARISON OF CUMULATIVE TOTAL RETURN (1) AMONG NATIONAL DENTEX (“NADX”), NASDAQ INDUSTRIAL INDEX AND PEER GROUP INDEX (2)

	12-31-02		12-31-03		12-31-04		12-31-05		12-31-06		12-31-07
NADX		100.00		122.82		155.84		173.03		134.34		122.21
NASDAQ		100.00		155.74		180.41		180.62		203.00		211.58
Peers		100.00		106.08		139.63		118.16		128.47		155.55

(1)	Assumes $100 invested on December 31, 2002 in our common stock, the NASDAQ Industrial Index and the Peer Group Index, including reinvestment of any dividends paid on the investment.
(2)	The Peer Group Index consists of Dentsply International, Inc. and Patterson Companies, Inc. We believe that these companies represent the other publicly traded companies within the dental service community.

11

Item 6.   Selected Financial Data

The following selected financial data for the five years ended December 31, 2007 are derived from our audited consolidated financial statements. The data should be read in conjunction with the consolidated financial statements and the related notes included in this Report and in conjunction with Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

	2003			2004		2005		2006		2007
	(Dollars in thousands, except per share data)
Consolidated Statements of Income:
Net sales	$	99,274		$	111,753	$	135,843	$	150,107	$	170,361
Cost of goods sold		59,534			66,953		78,381		88,269		97,739
Gross profit		39,740			44,800		57,462		61,838		72,622
Selling, general & administrative expenses		30,102			35,755		44,728		50,097		58,562
Operating income		9,638			9,045		12,734		11,741		14,060
Other expense		296			405		646		786		771
Interest (income) expense		(21	)		42		665		1,523		2,803
Income before provision for income taxes		9,363			8,598		11,423		9,432		10,486
Provision for income taxes		3,606			3,439		4,334		3,669		3,860
Net income	$	5,757		$	5,159	$	7,089	$	5,763	$	6,626
Net income per share — basic	$	1.12		$	0.99	$	1.33	$	1.05	$	1.20
Net income per share — diluted	$	1.10		$	0.94	$	1.27	$	1.01	$	1.17
Weighted average shares outstanding — basic		5,131			5,187		5,334		5,485		5,540
Weighted average shares outstanding — diluted		5,216			5,465		5,601		5,732		5,665
Consolidated Balance Sheet Data:
Working capital	$	12,252		$	13,750	$	11,126	$	6,232	$	6,000
Total assets		73,989			81,831		117,119		148,490		155,639
Long-term debt, including current portion		—			—		18,701		35,458		29,695
Stockholders’ equity	$	60,140		$	66,883	$	76,074	$	82,794	$	91,192

Item 7.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the Consolidated Financial Statements
and the related notes that appear elsewhere in this document.

Certain statements in this Annual Report, particularly statements contained in this Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate”, “believe”, “estimate”, “expect”, “plan”, “intend” and other similar expressions are intended to identify these forward-looking statements, but are not the exclusive means of identifying them. Forward-looking statements included in this Annual Report or hereafter included in other publicly available documents filed with the Securities and Exchange Commission (“SEC”), reports to our stockholders and other publicly available statements issued or released by us involve known and unknown risks, uncertainties, and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon our best estimates based upon current conditions and the most recent results of operations. Various risks, uncertainties and contingencies could cause our actual results, performance or achievements to differ materially from those expressed in, or implied by, the forward-looking statements contained in this Annual Report. These include,

12

but are not limited to, those described above under Item 1A, “Risk Factors.” We assume no obligation to update these forward-looking statements contained in this report, whether as a result of new information, future events, or otherwise.

Overview

We own and operate 48 dental laboratories located in 31 states and one Canadian province, serving an active customer base of over 24,000 dentists. Our business consists of the design, fabrication, marketing and sale of custom dental prosthetic appliances for dentists located primarily in the domestic marketplace.

Our products are grouped into the following three main categories:

Restorative Products.  Restorative products that our dental laboratories sell consist primarily of crowns and bridges. A crown replaces the part of a tooth that is visible, and is usually made of gold, porcelain or zirconia. A bridge is a restoration of one or more missing teeth that is permanently attached to the natural teeth or roots. In addition to the traditional crown, we also make porcelain jackets, which are crowns constructed entirely of porcelain; onlays, which are partial crowns which do not cover all of the visible tooth; and precision crowns, which are restorations designed to receive and connect a removable partial denture. We also make inlays, which are restorations made to fit a prepared tooth cavity and then cemented into place.

Reconstructive Products.  Reconstructive products sold by our dental laboratories consist primarily of partial dentures and full dentures. Partial dentures are removable dental prostheses that replace missing teeth and associated structures. Full dentures are dental prostheses that substitute for the total loss of teeth and associated structures. We also sell precision attachments, which connect a crown and an artificial prosthesis, and implants, which are fixtures anchored securely in the bone of the mouth to which a crown, partial or full denture is secured by means of screws or clips.

Cosmetic Products.  Cosmetic products sold by our dental laboratories consist primarily of porcelain veneers and ceramic crowns. Porcelain veneers are thin coverings of porcelain cemented to the front of a tooth to enhance personal appearance. Ceramic crowns are crowns made from ceramic materials that most closely replicate natural teeth. We also sell composite inlays and onlays, which replace silver fillings for a more natural appearance, and orthodontic appliances, which are products fabricated to move existing teeth to enhance function and appearance.

Recent Trends

During fiscal 2006, internal sales growth, meaning growth at laboratories held for longer than one year, was 2.8%, including the effect of increased prices due to underlying increases in the prices of precious metals. During fiscal 2007, internal sales growth was essentially flat with a sales decline of $503,000. We believe that the low cost segment for United States-based dental laboratories has begun to decline as competition from offshore laboratories, primarily those located in China, makes inroads into the domestic marketplace. While our business has not focused on this low cost segment of the market, we have experienced price pressures from other laboratories in our marketplaces that have restrained our ability to increase prices. During 2007, these increasing competitive pressures in the form of low price competition were partially responsible for declines in revenues or revenue growth in several marketplaces. In addition, we face growing competition from technology-based solutions that allow dentists to fabricate their own restorations without the use of a dental laboratory. Both of these trends appear to be impacting industry growth, and have been inhibiting our results of operations. Technology-based dental laboratory CAD-CAM manufacturing solutions have required us to make additional investments in capital equipment. We believe that these investments are critical to our business strategies.

The main components of our costs are labor and related employee benefits as well as raw materials, including precious metals. Over the past several years, competition for labor resources and increases in medical insurance premiums as well as volatility in the prices of many precious metals that we use, such as gold and palladium, have driven these costs higher. In 2007 we evaluated and adjusted staffing levels as appropriate at each of our locations, while continuing to recognize the need to maintain an available and properly trained workforce.

Since 2004 we have experienced cost pressures resulting from the implementation expenditures necessary to comply with Section 404 of the Sarbanes-Oxley Act. The impact of these various Section 404 implementation costs

13

on earnings for fiscal 2004 was approximately $1,027,000, or approximately $0.11 per diluted share, net of taxes. For fiscal 2005, these costs were approximately $720,000, or approximately $0.08 per diluted share, net of taxes, while in 2006, these costs were approximately $530,000, or approximately $0.06 per diluted share, net of taxes. In 2007, these costs further decreased to $402,000, or approximately $0.05 per diluted share, net of taxes, with the reduction primarily resulting from revisions to the standards governing the audit of internal control over financial reporting. Significant ongoing expenditures will continue to be required to maintain our compliance with the internal controls framework required by the Sarbanes-Oxley Act.

Acquisitions

We have also continued to pursue our acquisition strategy, which has played an important role in helping us increase sales from $99,274,000 in 2003 to $170,361,000 in 2007. We recognize acquired customer relationships and trade names as intangible assets which require the recognition of amortization expense (for the customer relationships) and impairment testing (for the customer relationships, trade names and goodwill). In March 2005, we completed what was then our largest acquisition to date, Green Dental Laboratories, Inc. (“Green”). Green is treated as a separate reportable segment for financial reporting purposes and retains a separate company identity as a wholly owned subsidiary. In October 2006, we completed our largest acquisition to date, that of Keller Group, Incorporated (“Keller”) of St. Louis, Missouri. Keller is also a wholly-owned subsidiary and is treated as a separate reportable segment for financial reporting purposes. Keller differs from National Dentex in its approach to marketing and to the marketplace. In recent years Keller has broadened its focus from local markets in the Midwest to the national marketplace. In order to sustain this strategy, Keller invests significantly in product advertising, primarily in dental print publications, and in direct mail. As a result, Keller has returned lower net margins than our other operating segments. However, it has obtained stronger sales growth and operating margins have improved. In January 2007, we announced a realignment of our corporate organization that reflects our recent acquisitions and is designed to help us better execute our operational strategy.

In order to finance the purchase of Green and Keller, we borrowed approximately $39,200,000 in long-term debt. Future acquisitions may also be financed using available debt financing. As a result of our acquisitions of Green and Keller, we are more highly leveraged than we were previously. Our interest expense has therefore become a more significant component of our pre-tax earnings. Interest expense in 2007 was $2,803,000 compared to $1,523,000 in 2006, $665,000 in 2005 and $42,000 in 2004.

Overview of Results of Operations

For the year ended December 31, 2007, sales increased $20,253,000 to $170,361,000, and net income increased $863,000. The acquisitions completed in the fourth quarter of 2006, Keller and Impact, were primarily responsible for this sales growth. In the NDX Laboratories operating segment, consisting of our laboratories other than Keller and Green, the consolidation of certain laboratories and departments, with the goal of improving segment profitability, led to the loss of certain customers and contributed to the decline in same laboratory sales. Same laboratory sales, measured by business at dental laboratories owned more than one year, declined $503,000 in the year ended December 31, 2007 compared to the prior year.

For the year ended December 31, 2007, gross profit increased by $555,000 within the NDX Laboratories operating segment, Green’s gross profit increased by $380,000 over the prior year and Keller contributed $9,061,000 of acquired gross profit and fourth quarter sales growth of 26.6%. Keller’s results for 2006 included only fourth quarter sales. Overall results benefited from staffing adjustments which lowered labor costs and related health insurance expense, as well as from increasing returns in laboratory technology investments. Same laboratory labor and benefits expenses declined $2,213,000 for the year ended December 31, 2007 compared to the prior year.

Liquidity and Capital Resources

On August 9, 2005 we entered into an amended and restated financing agreement (the “Amended Agreement”) with Bank of America, N.A. (the “Bank”). The Amended Agreement included a revolving line of credit of $5,000,000, a revolving acquisition line of credit of $20,000,000 and a term loan facility of $20,000,000. The interest rate on both revolving lines of credit and the term loan was the prime rate or, at our option, LIBOR, a cost of

14

funds rate, or the Bank’s fixed rate plus a range of 1.25% to 2.25% depending on the ratio of consolidated funded debt to consolidated “EBITDA”, as defined in the Amended Agreement. The Amended Agreement required monthly payments of principal on the term loan, based on a seven year amortization schedule, with a final payment due on the fifth anniversary of the Amended Agreement. The Amended Agreement required compliance with certain covenants, including the maintenance of specified net worth, income and other financial ratios.

In October 2006 we borrowed against our acquisition line of credit to finance our acquisition of Keller. In order to refinance the borrowings incurred for the Keller acquisition, we and the Bank executed a Second Amended and Restated Loan Agreement as of November 7, 2006 (the “Second Agreement”) comprising uncollateralized senior credit facilities totaling $60,000,000. The Second Agreement amended and restated the Amended Agreement (a) to increase the term loan facility to an aggregate principal amount of $35,000,000 and used the proceeds of the increase in the term loan to repay the portion of the outstanding principal balance under the acquisition line of credit and (b) to adjust the allocation of availability under the lines of credit by increasing the revolving line of credit to $10,000,000 ($5,000,000 of which may be used for future acquisitions) and decreasing the acquisition line of credit from $20,000,000 to $15,000,000. The interest rate on both lines of credit and the term loan is now the prime rate or, at our option, LIBOR, a cost of funds rate or the Bank’s fixed rate, plus, in each case, a range of 1.25% to 3.00%, depending on the ratio of consolidated total funded debt to consolidated “EBITDA”, as each is defined in the Second Agreement. The term loan facility portion of the Second Agreement requires monthly interest payments and monthly payments of principal, based on a seven year amortization schedule, with a final payment due on the fifth anniversary of the Second Agreement. The acquisition line of credit and the first line of credit mature on the third anniversary of the Second Agreement. The Second Agreement requires compliance with certain covenants, including the maintenance of specified net worth, income and other financial ratios. The Second Agreement was amended effective June 30, 2007 to revise certain financial targets within these covenants.

As of December 31, 2007, $5,453,000 was available under the revolving line of credit and $15,000,000 was available under the acquisition line of credit.

	December 31, 2006		December 31, 2007
Total long-term debt	$	35,458,000	$	29,695,000
Less: Current maturities		5,769,000		5,064,000
Long-term debt, less current portion	$	29,689,000	$	24,631,000

The table below reflects the expected repayment terms associated with the term loan facility at December 31, 2007. The interest rate associated with our borrowings was 7.8% as of December 31, 2007.

	December 31, 2007
	Principal Due
Fiscal 2008		5,064,000
Fiscal 2009		5,044,000
Fiscal 2010		5,004,000
Fiscal 2011		14,583,000
Total	$	29,695,000

Operating activities provided $12,552,000 in cash flow for the year ended December 31, 2007 compared to $11,089,000 during the year ended December 31, 2006, an increase of $1,463,000. Our working capital decreased slightly from $6,232,000 at December 31, 2006 to $6,000,000 at December 31, 2007. This decrease was primarily attributable to increases in current bank debt of $2,499,000; increases in accounts payable and accrued liabilities of $1,805,000, primarily related to income tax accruals, offset by: increases in prepaid expenses of $2,393,000, primarily related to increases in prepaid insurance and prepaid income taxes due to timing differences in our payments; increases in accounts receivable of $620,000, primarily related to increases in income tax refunds; and increases in cash balances of $1,041,000.

Investing activities consumed $9,851,000 in cash flow for the year ended December 31, 2007 compared to $29,086,000 during the year ended December 31, 2006, a decrease of $19,235,000. Cash outflows related to

15

payments for acquisitions, including deferred purchase price payments associated with prior period dental laboratory acquisitions, totaled $2,159,000 for the year ended December 31, 2007, compared to $24,608,000 for the year ended December 31, 2006, which resulted primarily from the acquisition of Keller. Capital expenditures increased from $4,899,000 at December 31, 2006 to $7,536,000 at December 31, 2007 primarily due to leasehold improvements for new facilities.

In financing activities, current liabilities attributed to bank debt increased $2,499,000 during fiscal 2007. Amounts borrowed on our revolving line of credit increased by $3,204,000, primarily due to new facility expenditures while the current portion of long term debt declined $705,000 as a result of the payment of acquired bank debt related to the acquisition of Keller. Long-term bank debt, less the current portion, declined $5,058,000 to $24,631,000 at December 31, 2007 from $29,689,000 at December 31, 2006 as a result of scheduled term loan repayments. We believe that cash flow from operations and available financing will be sufficient to meet contemplated operating and capital requirements such as those discussed below, for the foreseeable future.

Commitments and Contingencies

The following table represents a list of our contractual obligations and commitments as of December 31, 2007:

	Payments Due By Period
			Less Than						Greater Than
	Total		1 Year		1 - 3 Years		4 - 5 Years		5 Years
Term Loan Facility	$	29,583,000	$	5,000,000	$	10,000,000	$	14,583,000		—
Interest Expense		5,978,000		2,118,000		3,054,000		806,000		—
Capital Leases		111,000		64,000		47,000		—		—
Operating Leases:
Real Estate		21,190,000		3,351,000		6,177,000		5,013,000		6,649,000
Vehicles		755,000		572,000		182,000		1,000		—
Equipment		225,000		105,000		94,000		26,000		—
Construction Contracts		728,000		728,000		—		—		—
Laboratory Purchase Obligations		1,579,000		1,279,000		300,000		—		—
Contingent Laboratory Purchase Price		300,000		300,000		—		—		—
TOTAL	$	60,449,000	$	13,517,000	$	19,854,000	$	20,429,000	$	6,649,000

Bank borrowings on the term loan facility, with repayment terms greater than one year, are classified as long-term debt on the balance sheet. Interest expense payments, included in the above table, related to the term loan facility have been projected using the interest rate associated with current borrowings.

We are committed under various non-cancelable operating lease agreements covering office space and dental laboratory facilities, vehicles and certain equipment. Certain of these leases also require us to pay maintenance, repairs, insurance and related taxes.

Laboratory purchase obligations totaling $1,579,000, classified as deferred acquisition costs, are presented in the liability section of the balance sheet. These obligations, including deferred obligations associated with non-competition agreements, represent purchase price commitments arising from dental laboratory acquisitions, irrespective of the acquired laboratory’s earnings performance. Contingent laboratory purchase price includes amounts subject to acquisition agreements that are tied to laboratory earnings performance, as defined within the acquisition agreements, generally over a three year period. As payments become determinable, they are recorded in our purchase price allocation. The amount included in the table represents the maximum contractual amount that could be paid under the agreements.

16

Results of Operations

Our results are reported within three operating segments, NDX Laboratories, Green Dental and Keller. The following table sets forth for the periods indicated the percentage of net sales represented by certain items in our Consolidated Financial Statements:

	Years Ended December 31,
	2005			2006			2007
Net sales		100.0	%		100.0	%		100.0	%
Cost of goods sold		57.7			58.8			57.4
Gross profit		42.3			41.2			42.6
Selling, general and administrative expenses		32.9			33.4			34.3
Operating income		9.4			7.8			8.3
Other expense		0.5			0.5			0.5
Interest expense		0.5			1.0			1.6
Income before provision for income taxes		8.4			6.3			6.2
Provision for income taxes		3.2			2.5			2.3
Net income		5.2	%		3.8	%		3.9	%

Year Ended December 31, 2007 Compared with Year Ended December 31, 2006

Net Sales

For the year ended December 31, 2007, net sales increased $20,253,000 or 13.5% over the prior year. Net sales increased by approximately $20,756,000, primarily as a result of acquisitions measured by business at dental laboratories owned less than one year. Net sales decreased approximately $503,000 at dental laboratories owned for both the year ended December 31, 2007 and the year ended December 31, 2006, primarily as a result of sales declines in the NDX Laboratories operating segment. Competitive pressures from offshore laboratories that can produce crowns at fees lower than crowns manufactured in the United States continue to limit our ability to raise our prices during a time when we have experienced relatively higher costs for precious metals used in manufacturing. In addition, these competitive pressures are partially responsible for declines in revenues or revenue growth in several marketplaces.

Cost of Goods Sold

Our cost of goods sold increased by $9,469,000 or 10.7% in the year ended December 31, 2007 over the year ended December 31, 2006. As a percentage of sales, cost of goods sold decreased from 58.8% to 57.4%, primarily resulting from decreases in labor and related benefits, partially offset by increases in materials expense and laboratory overhead. Excluding acquisitions, production labor and related benefits decreased by approximately $1,881,000 for the year ended December 31, 2007 compared to the year ended December 31, 2006 primarily due to reductions in our staffing levels at certain laboratories. The cost of raw materials as a percentage of sales increased from 15.2% for the year ended December 31, 2006 to 15.7% for the year ended December 31, 2007. In 2007 the average cost of precious metals used as components of many dental alloys, including gold and palladium, increased by approximately 15.3% for gold and 10.6% for palladium over average costs in the prior year. During the fourth quarter of 2007, the average cost of gold increased by 31.9% over the average cost in the fourth quarter of 2006. Although we are able to pass a portion of precious metal cost increases on to our customers, prolonged higher metal costs have had and likely will continue to have a negative impact on gross profit percentages.

Overall, labor expense as a percentage of sales for the year ended December 31, 2007 improved over the year ended December 31, 2006. As a percentage of sales, production labor and related benefits declined from 35.5% in 2006 to 33.1% in 2007. Green’s labor costs of 28.8% of sales and Keller’s labor costs of 22.9% of sales lowered the overall percentage while the portion attributable to NDX Laboratories decreased to 35.7% of sales for the year ended December 31, 2007 from 36.8% for the year ended December 31, 2006.

17

Selling, General and Administrative Expenses

Operating expenses, which consist of selling, delivery and administrative expenses both at the laboratory and corporate level, increased by $8,465,000 or 16.9% in the year ended December 31, 2007 compared to 2006. Operating expenses increased as a percentage of net sales from 33.4% in 2006 to 34.3% in 2007. As a percentage of sales, delivery expenses increased from 8.9% in the year ended December 31, 2006 to 9.2% in 2007. Selling expenses increased from 5.1% of sales for the year ended December 31, 2006 to 6.2% in 2007. Selling expenses in 2007 for the Keller segment were 14.5% of sales, or $3,454,000. Laboratory incentive compensation decreased from 2.7% of sales in 2006 to 2.3% in 2007, while the amount decreased by $209,000 from $4,081,000 for the year ended December 31, 2006 to $3,872,000 in 2007. Executive incentive compensation expense increased by $298,000 to $448,000 for the year ended December 31, 2007 from $150,000 for the year ended December 31, 2006, as a result of achievement of plan objectives.

The increase of $8,465,000 in our operating expenses in 2007 was primarily attributable to the following increases:

•  Additional operating costs associated with recent acquisitions — $7,078,000;

•  Increases in salaries and benefits at the corporate level due to additional management staff, net of related reductions in consulting expense — $895,000;

•  Increases in executive incentive compensation — $298,000;

•  Increases in deferred compensation and post-retirement medical benefits, net of increases in related cash surrender value of life insurance policies — $158,000;

•  Increases in delivery expenses, excluding salaries and benefits — $330,000;

•  Increases in selling expenses, including $175,000 in increased compensation — $251,000; and

•  Absence of gains on the sale of fixed assets in 2007, compared with the gain recorded in 2006 primarily resulting from the sale of our former laboratory facility in Houston, Texas — $479,000;

partially offset by:

•  Decreases in administrative and delivery salaries and benefits at the laboratory level — $655,000;

•  Decreases in health insurance expense — $137,000; and

•  Decreases in laboratory incentive compensation — $209,000.

Operating Income

As a result of the above factors, our operating income increased by $2,319,000 to $14,060,000 for the year ended December 31, 2007 from $11,741,000 in 2006. As a percentage of net sales, operating income increased from 7.8% in 2006 to 8.3% in 2007, primarily as a result of improvements in gross margin as a result of reductions in staffing levels.

Interest Expense

Interest expense increased $1,280,000 from $1,523,000 for the year ended December 31, 2006 to $2,803,000 for 2007, primarily as a result of our increased bank borrowings to fund our acquisition of Keller late in 2006.

Provision for Income Taxes

The provision for income taxes increased by $191,000 to $3,860,000 for the year ended December 31, 2007 from $3,669,000 in 2006. The 36.8% effective tax rate estimated for fiscal year 2007 declined from the 38.9% effective tax rate for 2006. The decrease in the effective tax rate for 2007 was due in part to recognition of lower federal tax expense resulting from the domestic manufacturing tax credit provisions of the American Jobs Creation Act of 2004.

18

Net Income

As a result of all the factors discussed above, net income increased $863,000 to $6,626,000 or $1.17 per share on a diluted basis for the year ended December 31, 2007 from $5,763,000 or $1.01 per share on a diluted basis in 2006.

Operating Segment Results

Our business consists of a single industry segment, which is the design, fabrication, marketing and sale of custom dental prosthetic appliances for and to dentists in North America. We report on three operating segments within this single industry segment. These three segments are known as Green Dental, representing the operations of Green Dental Laboratories, Inc. of Heber Springs, Arkansas which we acquired in March 2005; Keller, representing the operations of Keller Group, Incorporated with laboratories in St. Louis, Missouri and Louisville, Kentucky, which we acquired in October, 2006; and NDX Laboratories, which represents our remaining laboratories, including Impact Dental Laboratory Limited, which we acquired in October, 2006.

	Year Ended December 31
	2006		2007		$ Change			% Change
Revenue:
NDX Laboratories	$	126,543,054	$	127,388,588	$	845,534			.7	%
Green Dental		18,817,607		19,859,770		1,042,163			5.5	%
Keller		4,863,988		23,843,093		18,979,105			—
Subtotal		150,224,649		171,091,451		20,866,802			13.9	%
Less: Inter-segment Revenues:
NDX Laboratories		—		370,913		370,913			—
Green Dental		117,242		199,525		82,283			70.2	%
Keller		—		160,384		160,384			—
Net Sales	$	150,107,407	$	170,360,629	$	20,253,222			13.5	%
Laboratory Operating Income:
NDX Laboratories	$	16,840,606	$	17,572,491	$	731,885			4.3	%
Green Dental		4,820,007		4,665,630		(154,377	)		(3.2	)%
Keller		446,151		3,228,640		2,782,489			—
Laboratory Operating Income	$	22,106,764	$	25,466,761	$	3,359,997			15.2	%

NDX Laboratories

For the year ended December 31, 2007, sales growth in this segment of 0.4% consisted of a 2.2% reduction in same laboratory sales offset by 2.6% in sales growth attributable to the October 2006 acquisition of Impact. The reduction in internal sales resulted primarily from the loss of certain customers as we consolidated certain laboratories and departments, with the goal of improving long-term profitability. Several laboratories in this segment also experienced lower unit volumes as they were impacted by increased competitive pressures in the form of low price competition.

Gross profit as a percentage of sales increased from 39.9% for the year ended December 31, 2006 to 40.3% for the year ended December 31, 2007. Cost of goods sold decreased by $323,000. The decrease was attributable to decreases in manufacturing labor and benefits of approximately $2,376,000 primarily resulting from reductions in staffing levels and associated decreases in health insurance costs and decreases in the cost of materials of approximately $269,000, offset by additional costs related to acquisitions of $1,866,000 and laboratory overhead increases of approximately $457,000 resulting from new facilities and higher energy costs.

Laboratory operating income as a percentage of sales for NDX Laboratories increased from 13.3% for the year ended December 31, 2006 to 13.9% for the year ended December 31, 2007 as a result of the factors discussed above.

19

Green Dental

For the year ended December 31, 2007, internal sales growth in this segment was 5.1%. As a percentage of sales, gross profit decreased from 48.0% for the year ended December 31, 2006 to 47.4% for the year ended December 31, 2007, primarily the result of increases in materials cost, including precious metals. Laboratory operating income as a percentage of sales for Green declined from 25.6% for the year ended December 31, 2006 to 23.5% for the year ended December 31, 2007. The decline was primarily attributable to increased selling expenses, primarily compensation, and lower property disposal gains.

Keller

This segment resulted from our acquisition of Keller Group, Inc. effective October 2, 2006. While sales growth in the first nine months of 2007 was all attributable to the acquisition, sales in the fourth quarter of 2007 grew by 26.6% over the fourth quarter of 2006, the first in which we owned Keller. Keller operates with manufacturing efficiencies but also is pursuing growth with significant spending in product advertising, primarily in dental print publications and direct mail. As a result, while Keller returned lower net operating margins than our other operating segments, it has achieved significantly higher sales growth. Laboratory operating income as a percentage of sales improved to 13.5% for the year ended December 31, 2007 compared to 9.2% for the quarter ended December 31, 2006. Gross profit as a percentage of sales improved to 51.0% for the year ended December 31, 2007 compared to 47.5% for the quarter ended December 31, 2006.

Year Ended December 31, 2006 Compared with Year Ended December 31, 2005

Net Sales

For the year ended December 31, 2006, net sales increased $14,265,000 or 10.5% over the prior year. Net sales increased by approximately $10,443,000 as a result of acquisitions, measured by business at dental laboratories owned less than one year. Net sales increased approximately $3,822,000 or 2.8% at dental laboratories owned for both the year ended December 31, 2006 and the year ended December 31, 2005, primarily as a result of price increases, most of which passed along some, but not all, of our higher precious metal costs to our customers. Competitive pressures from offshore laboratories that can produce crowns at fees lower than crowns manufactured in the United States have limited our ability to raise our prices during a time when have experienced higher than usual costs for precious metals used in manufacturing. As a result, gross and net margins were unfavorably impacted.

Cost of Goods Sold

Our cost of goods sold increased by $9,889,000 or 12.6% in the fiscal year ended December 31, 2006 over the prior fiscal year. As a percentage of sales, cost of goods sold increased from 57.7% to 58.8%. The increase, which was primarily attributable to the NDX Laboratories segment due to product mix, was mainly the result of increases in the cost of precious metals. The cost of raw materials as a percentage of sales increased from 13.7% for the year ended December 31, 2005 to 15.2% for the year ended December 31, 2006. The average cost of precious metals used as components of many dental alloys, including gold and palladium, increased approximately 35.7% for gold and 59.0% for palladium, over average costs in 2005. Although we are able to pass a portion of precious metal cost increases on to our customers, prolonged higher metal costs have had and likely will continue to have a negative impact on gross profit percentages.

Overall, labor expense as a percentage of sales for the year ended December 31, 2006 improved over the year ended December 31, 2005. As a percentage of sales, production labor and related benefits declined from 36.3% in 2005 to 35.5% in 2006. Green’s labor costs of 29.0% of sales for the year ended December 31, 2006 and Keller’s labor costs of 25.0% of sales in the fourth quarter of 2006 lowered the overall percentage while the portion attributable to NDX Laboratories declined slightly to 36.8% of sales for the year ended December 31, 2006 from 37.0% for the year ended December 31, 2005.

20

Selling, General and Administrative Expenses

Operating expenses, which consist of selling, delivery and administrative expenses both at the laboratory and corporate level, increased by $5,368,000 or 12.0% in the year ended December 31, 2006 compared to 2005. Operating expenses increased as a percentage of net sales from 32.9% in 2005 to 33.4% in 2006. As a percentage of sales, delivery expenses increased from 8.0% in the year ended December 31, 2005 to 8.9% in 2006, due to higher delivery costs, including rising fuel costs and additional salaries. Selling expenses increased from 4.3% of sales for the year ended December 31, 2005 to 5.1% in 2006. Selling expenses in the fourth quarter of 2006 for the Keller segment were 18.2% of sales, or $884,000 while spending on promotional materials and customer loyalty programs increased by approximately $500,000 for the year ended December 31, 2006. Administrative expenses decreased from 16.2% of sales for the year ended December 31, 2005 to 15.7% in 2006 and laboratory incentive compensation decreased from 3.3% of sales in 2005 to 2.7% in 2006 as a result of decreased earnings performance at certain laboratories.

The increase of $5,368,000 in our operating expenses in 2006 was primarily attributable to the following increases:

•  Additional operating costs and amortization expense associated with recent acquisitions — $3,109,000;

•  Increases in salaries and benefits at the corporate and laboratory level, in part due to additional finance and management staff and increases in health insurance — $737,000;

•  Increases in rent expense, including additional rent related to facilities under construction — $227,000;

•  Increases in spending on voluntary OSHA training and maintenance programs — $120,000;

•  Increases in delivery costs — $1,900,000;

•  Increases in selling expenses, including promotional materials and customer loyalty programs — $677,000; and

•  Impairment of fixed assets in 2006 — $161,000;

partially offset by:

•  Decreases in laboratory and executive incentive compensation as a result of laboratory profit performance — $881,000;

•  Decreases in consulting expenses and professional fees, including audit and compliance costs — $168,000;

•  Decreases in bad debt expense due to collections results and current receivable profile — $154,000; and

•  The gain from the sale of our former laboratory facility in Houston, Texas — $397,000.

Operating Income

As a result of the above factors, our operating income decreased by $993,000 to $11,741,000 for the year ended December 31, 2006 from $12,734,000 in 2005. As a percentage of net sales, operating income declined from 9.4% in 2005 to 7.8% in 2006.

Interest Expense

Interest expense increased $858,000 from $665,000 for the year ended December 31, 2005 to $1,523,000 in 2006, primarily as a result of our increased bank borrowings to fund our acquisitions of Green and Keller and rising interest rates.

Provision for Income Taxes

The provision for income taxes decreased by $665,000 to $3,669,000 for the year ended December 31, 2006 from $4,334,000 in 2005. The 37.9% effective tax rate for fiscal year 2005 increased to 38.9% for fiscal year 2006.

21

Net Income

As a result of all the factors discussed above, net income decreased $1,326,000 to $5,763,000 or $1.01 per share on a diluted basis for the year ended December 31, 2006 from $7,089,000 or $1.27 per share on a diluted basis in 2005.

Operating Segment Results

Our business consists of a single industry segment, which is the design, fabrication, marketing and sale of custom dental prosthetic appliances for and to dentists in North America. We report on three operating segments within this single industry segment. These three segments are known as Green Dental, representing the operations of Green Dental Laboratories, Inc. of Heber Springs, Arkansas which we acquired in March 2005; Keller, representing the operations of Keller Group, Incorporated with laboratories in St. Louis, Missouri and Louisville, Kentucky which we acquired in October, 2006; and NDX Laboratories, which represents our remaining laboratories, including Impact Dental Laboratory Limited, which we acquired in October, 2006.

	Year Ended December 31
	2005		2006		$ Change			% Change
Revenue:
NDX Laboratories	$	121,370,004	$	126,543,054	$	5,173,050			4.3	%
Green Dental		14,513,115		18,817,607		4,304,492			29.7	%
Keller		—		4,863,988		4,863,988			—
Subtotal		135,883,119		150,224,649		14,341,530			10.6	%
Less: Inter-segment Revenues:		40,445		117,242		76,797			—
Net Sales	$	135,842,674	$	150,107,407	$	14,264,733			10.5	%
Laboratory Operating Income:
NDX Laboratories	$	19,586,603	$	16,840,606	$	(2,745,997	)		(14.2	)%
Green Dental		3,571,803		4,820,007		1,248,204			34.9	%
Keller		—		446,151		446,151			—
Laboratory Operating Income	$	23,158,406	$	22,106,764	$	(1,051,642	)		(4.5	)%

NDX Laboratories

The net sales growth in this segment of 4.3% included internal growth of 3.2% and growth related to laboratory acquisitions of 1.1%. The majority of the internal growth was the result of commodity cost increases on precious metals, a portion of which was passed on to our customers.

Gross profit as a percentage of sales decreased from 41.7% for the year ended December 31, 2005 to 39.9% for the year ended December 31, 2006. Cost of goods sold increased by $5,181,000. The increase was attributable to additional costs from acquisitions of $831,000, increases in the cost of materials, primarily precious metals, of approximately $2,092,000, increases in manufacturing labor and benefits of approximately $1,205,000, resulting from an increase in health insurance costs and excess capacity, and laboratory overhead increases of approximately $1,053,000 resulting from new facilities and higher energy costs.

Laboratory operating income as a percentage of sales for NDX Laboratories decreased from 16.1% for the year ended December 31, 2005 to 13.3% for the year ended December 31, 2006 primarily as a result of the above factors.

Green Dental

The net sales growth in this segment of 29.7% included internal growth of 9.0% and 20.7% of growth related to the comparison of twelve months of operations in 2006 compared to ten months of operations in 2005. As a percentage of sales, gross profit increased from 47.5% in 2005 to 48.0% in 2006. Manufacturing labor and benefit decreases were partially offset by increases in materials costs. Laboratory operating income as a percentage of sales

22

for Green increased from 24.6% for the year ended December 31, 2005 to 25.6% for the year ended December 31, 2006.

Keller

This segment is the result of our acquisition of Keller Group, Inc. effective October 2, 2006, and therefore the sales are entirely attributable to acquisition growth. Keller operates with manufacturing efficiencies but also is pursuing growth with significant spending in product advertising, primarily in dental print publications. As a result, we expect Keller to return lower net margins initially than our other operating segments but conversely expect it to obtain stronger sales growth prospectively.

Gross profit as a percentage of sales for the fourth quarter of 2006 was 47.5%. Laboratory operating income as a percentage of sales for Keller was 9.2% in the fourth quarter of 2006. The operating income performance from the fourth quarter of 2006 does not represent the expected results for full fiscal periods in 2007.

Critical Accounting Policies

Financial Reporting Release No. 60 as released by the SEC requires all companies to include a discussion of critical accounting policies or methods used in the preparation of financial statements. The preparation of our consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting period. A summary of certain of our significant accounting policies is presented below.

Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized upon transfer of title and risk of loss, generally as the dentists’ orders are shipped. We record shipping and handling fees charged to customers as revenues in accordance with EITF 00-10 “Accounting for Shipping and Handling Fees and Costs.” Shipping and handling costs totaled approximately $10,852,000 in fiscal 2005, $13,365,000 in fiscal 2006 and $15,617,000 in fiscal 2007, and are included in selling, general and administrative expense.

Goodwill and Other Indefinite-Lived Intangible Assets Not Subject to Amortization

In accordance with Statement of Financial Accounting Standards (“SFAS”) No. 142 “Goodwill and Other Intangible Assets” (“SFAS 142”), goodwill amortization ceased on December 31, 2001. We continually evaluate whether events and circumstances have occurred that indicate that the value of goodwill has been impaired. In accordance with SFAS No. 142, goodwill is evaluated for possible impairment on an annual basis, based on a two-step process. The first step is to compare the fair value of the reporting unit to its carrying amount to determine if there is potential impairment. The second step, used to measure the amount of impairment loss, compares the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. In accordance with SFAS No. 142, the reporting unit is an operating segment or one level below an operating segment (referred to as a component). We view the individual laboratories as reporting units. We determine fair value using factors based on revenue and operating margins. In the second quarter of 2005, 2006 and 2007 we completed the annual impairment testing and determined that no impairment existed.

Additionally, we also recognize the existence of value in trade names acquired in business combinations and believe the useful life of this intangible to be indefinite. Accordingly, trade names are also evaluated for impairment on an annual basis using a single-step method in accordance with SFAS No. 142. Impairment charges related to trade names are recognized when the fair value is less than the carrying value of the asset. Impairment charges of $10,000, $47,000 and $94,000 were recorded in the year ended December 31, 2005, 2006 and 2007, respectively. Trade name impairment charges generally result from a decline in forecasted revenue at specific laboratories in comparison to revenue forecasts used in previous valuation calculations.

23

Intangible Assets Subject to Amortization

We follow the applicable accounting pronouncements — specifically SFAS No. 141 “Business Combinations” and Emerging Issues Task Force Abstract 02-17 “Recognition of Customer Relationship Intangible Assets Acquired in a Business Combination” (“EITF 02-17”), in accounting for purchase business combinations. Non-competition agreements and customer relationship intangibles arising from dental laboratory acquisitions are amortized over their useful lives. The acquisition date fair value of non-competition agreements are deferred and amortized over their economic useful lives, in accordance with the terms of the agreements, ranging from 2 to 15 years. The acquisition date fair value associated with acquired customer relationships are amortized over their estimated economic useful life, ranging from 9 to 12 years.

Inventories

Inventories, consisting principally of raw materials, are stated at the lower of cost (first-in, first-out) or market. We use estimates based on specific identification to maintain proper reserves for excess and obsolete inventory. Additionally, we estimate work in process inventories by applying current labor, materials and selected overhead expense rates to standard production schedules. We estimate the value of unrefined precious metal scrap based on the application of various return and refining statistics. Finished goods inventory consists of completed orders that were shipped to customers immediately subsequent to period end.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the following estimated depreciable lives:

Buildings	25 years
Furniture and fixtures	5 - 10 years
Laboratory equipment	5 - 20 years
Computer equipment	3 - 5 years

Leasehold improvements and capital leases are amortized over the lesser of the assets’ estimated useful lives or the lease terms.

Gains and losses are recognized upon the disposal of property and equipment, and the related accumulated depreciation and amortization are removed from the accounts. Maintenance, repairs and betterments that do not enhance the value of or increase the life of the assets are charged to operations as incurred.

Depreciation expense totaled approximately $2,372,000 in fiscal 2005, $3,135,000 in fiscal 2006 and $4,055,000 in fiscal 2007.

Impairment of Long-Lived Assets

At each balance sheet date, management evaluates the recoverability of long-lived assets, including property and equipment and intangible assets, using certain financial indicators, such as historical and future ability to generate income from operations. Our policy is to assess whether an impairment exists in the period when it is determined that the carrying amount of the asset may not be recoverable. The determination is based on an evaluation of such factors as the occurrence of a significant event, a significant change in the environment in which the business operates or if the expected future cash flows become less than the carrying amount of the asset.

Cash Surrender of Life Insurance

The cash surrender value of life insurance policies are recorded at net realizable value.

Income Taxes

We follow SFAS No. 109, “Accounting for Income Taxes”. Under SFAS No. 109, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. The amount of deferred tax asset or liability is based on the difference between the

24

financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We have considered our current financial characteristics as well as current tax law and do not believe that the recoverability of various tax assets and liabilities is impaired, and therefore have recorded them at their full value.

We also follow FASB issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes-an Interpretation of FASB Statement No. 109”, (“FIN 48”).” FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The minimum threshold is defined in FIN 48 as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS No. 157”), “Fair Value Measurements.” Among other requirements, SFAS 157 defines fair value and establishes a framework for measuring fair value and also expands disclosure about the use of fair value to measure assets and liabilities. SFAS 157 prescribes a single definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. SFAS 157 is effective beginning the first fiscal year that begins after November 15, 2007. However, in January 2008, the FASB issued FASB Staff Position FAS 157-b, “Effective Date of FASB Statement No. 157” (“FSP FAS 157-b”). This FSP permits entities to elect to defer the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. We have elected to defer the adoption of SFAS No. 157 for those assets and liabilities included in FSP FAS 157-b. We believe the adoption of SFAS No. 157 will not have a material impact on our financial position and results of operations.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities”, including an amendment of FASB Statement No. 115 (“SFAS No. 159”). SFAS No. 159 permits entities to choose, at specified election dates, to measure eligible items at fair value (the “fair value option”). A business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting period. This accounting standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. We believe the adoption of SFAS No. 159 will not have a material impact on our financial position and results of operations.

In December 2007, the FASB issued FAS No. 141 (Revised 2007), “Business Combinations” (“FAS 141(R)”). FAS 141(R) establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements, the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree. The statement also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of business combinations. FAS 141(R) is effective on a prospective basis for financial statements issued for fiscal years beginning after December 15, 2008. Accordingly, any business combination we enter into after December 31, 2008 will be subject to this new standard.

Item 7A.   Quantitative and Qualitative Disclosures about Market Risk

Our market risk exposure includes potential price volatility of commodities we use in our manufacturing processes. We purchase dental alloys that contain gold, palladium and other precious metals. We have not participated in hedging transactions. We have relied on pricing practices that attempt to pass some portion, if not all, of our increased costs on to our customers, in conjunction with materials substitution strategies.

At December 31, 2007, we had variable rate debt of $34.2 million. Based on this amount, the earnings and cash flows impact for the next year resulting from a one percentage point increase in interest rates would be approximately $213,000, net of tax, holding other variables constant.

25

We have investments in a foreign subsidiary. The net assets of this subsidiary are exposed to volatility in current exchange rates. We have determined that the effect of a 1% change in exchange rates would be immaterial to our results of operations and financial position.

Item 8.   Financial Statements and Supplementary Data

Quarterly Results

The following table sets forth certain selected financial information for the eight fiscal quarters in our two most recently completed fiscal years. In our opinion, this unaudited information has been prepared on the same basis as the audited financial information and includes all adjustments (consisting of only normal, recurring adjustments) necessary to present this information fairly when reviewed in conjunction with our Consolidated Financial Statements and notes thereto contained herein.

	Three Months Ended
	March 31,			June 30,			Sept. 30,			Dec. 31,			March 31,			June 30,			Sept. 30,			Dec. 31,
	2006			2006			2006			2006			2007			2007			2007			2007
	(Dollars in thousands except per share data)
Net sales	$	36,789		$	38,116		$	34,613		$	40,589		$	43,343		$	44,434		$	41,204		$	41,380
Gross profit	$	15,928		$	16,292		$	13,468		$	16,150		$	19,060		$	19,560		$	17,491		$	16,510
Gross margin		43.3	%		42.7	%		38.9	%		39.8	%		44.0	%		44.0	%		42.4	%		39.9	%
Operating income	$	3,961		$	4,345		$	1,926		$	1,510		$	4,520		$	4,875		$	3,036		$	1,630
Operating margin		10.8	%		11.4	%		5.6	%		3.7	%		10.4	%		11.0	%		7.4	%		3.9	%
Net income	$	2,150		$	2,320		$	925		$	369		$	2,244		$	2,417		$	1,308		$	656
Net income per diluted share	$	0.38		$	0.40		$	0.16		$	0.06		$	0.40		$	0.43		$	0.23		$	0.12

Our results of operations have historically fluctuated on a quarterly basis and are expected to be subject to quarterly fluctuations in the future. As a result, we believe that the results of operations for the interim periods are not necessarily indicative of the results to be expected for any future period or for a full year. Quarterly results are subject to fluctuations resulting from a number of factors, including the number of working days in the quarter for both dentists and our employees, the number of paid vacation days and holidays in the period, general economic conditions and consumer spending patterns. Historically, the second quarter has generated the highest quarterly net sales for the year and has been the most profitable for us due to the greater number of working days in the quarter and more patients scheduling visits with their dentists before departing for summer vacation.

Location of Financial Statements

The consolidated financial statements furnished in connection with this Report are attached immediately following Part IV.

Item 9.   Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A.   Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We carried out an evaluation, with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures as of December 31, 2007. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applied its judgment in evaluation of the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of December 31, 2007, our disclosure controls and procedures, as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) and 15d-15(e), were effective to ensure that information required to be

26

disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and such information is accumulated and communicated to management, including the CEO and CFO, to allow timely decisions regarding required disclosure.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we carried out an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2007 based on the Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based upon this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2007.

PricewaterhouseCoopers LLP, the independent registered public accounting firm that audited our financial statements included in this Annual Report on Form 10-K, has also audited the effectiveness of internal control over financial reporting as of December 31, 2007, as stated in their report which is included herein.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended December 31, 2007 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9A(T).   Controls and Procedures

Not applicable.

Item 9B.   Other Information

None.

PART III

Item 10.   Directors, Executive Officers and Corporate Governance

The information required by this Item will be contained in our proxy statement for the annual meeting of stockholders scheduled to be held on May 13, 2008, which we plan to file with the SEC on or about April 7, 2008, but in no event later than 120 days after the end of our fiscal year ended December 31, 2007 (the “2008 Proxy Statement”). Such information is hereby incorporated by reference.

We have adopted a written code of business conduct and ethics that applies to all our directors, officers and employees, a copy of which is located on the Investor Relations page of our website which is located at www.nationaldentex.com. We intend to disclose any amendments to, or waivers from, our code of business conduct and ethics on that same page of our website.

Item 11.   Executive Compensation

The information required by this item will be included in our 2008 Proxy Statement and is incorporated herein by reference.

Item 12.   Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

The information required by this item will be included in our 2008 Proxy Statement and is incorporated herein by reference.

27

Equity Compensation Plan Information

We maintain two stock incentive plans that were approved by our Board of Directors (the “Board”). In 1992, the Board and stockholders adopted the 1992 Long-Term Incentive Plan (“1992 LTIP”). Key employees, officers and directors were eligible to receive grants under the plan. No additional options may be granted under this plan. In January 2001, the Board adopted the 2001 Stock Plan (“2001 Plan”), which was approved by our stockholders in April 2001. Key employees, officers and directors are eligible to receive grants under the plan. On May 16, 2006, our shareholders approved an amendment to the 2001 Plan at our annual meeting of stockholders to allow for the issuance of restricted stock and restricted stock units. In addition, we maintain an Employee Stock Purchase Plan (“ESPP”) that is qualified under Section 423 of the Internal Revenue Code. On May 15, 2007, our shareholders approved an amendment to the ESPP at our annual meeting of stockholders to allow for the issuance of an additional 150,000 shares.

These plans are discussed in further detail in Note 9 of our Consolidated Financial Statements, which are furnished in connection with Item 8 of this Annual Report on Form 10-K and are attached immediately following Part IV below. Summary plan information as of December 31, 2007 is as follows:

	Number of Shares of
	National Dentex				Number of Shares of
	Corporation				National Dentex
	Common Stock to				Corporation
	Be Issued Upon		Weighted Average		Common Stock
	Exercise of		Exercise Price of		Remaining Available
	Outstanding Options		Outstanding Options		for Future Issuance
1992 LTIP		243,565	$	11.79		None
2001 Plan		318,000	$	14.53		392,057
ESPP		—		—		150,000
Total		561,565	$	13.34		542,057

Item 13.   Certain Relationships and Related Transactions

The information required by this item will be included in our 2008 Proxy Statement and is incorporated herein by reference.

Item 14.   Principal Accountant Fees and Services

The information required by this item will be included in our 2008 Proxy Statement under the caption “Independent Auditors’ Fees and Other Matters”, and is incorporated herein by reference.

PART IV

Item 15.   Exhibits and Financial Statement Schedules

(a) 1. Financial statements:

For a listing of consolidated financial statements which are included in this Report, see page F-1.

2. Financial Statement Schedules:

All schedules for which provision is made under Item 15(a)(2) are inapplicable and, therefore, have been omitted.

3. Exhibits:

The exhibits listed in the Exhibit Index immediately preceding the exhibits are filed as part of this Annual Report on Form 10-K and are incorporated herein by reference.

(b) Exhibits:

The exhibits listed in the Exhibit Index immediately preceding the exhibits are filed as part of this Annual Report on Form 10-K and are incorporated herein by reference.

(c) Financial Statement Schedules:

Included in Item 15(a)(2) above.

28

NATIONAL DENTEX CORPORATION

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SCHEDULE

	Page
Financial Statements:
The consolidated financial statements of National Dentex Corporation included herein are as listed below:
Report of Independent Registered Public Accounting Firm		F-2
Consolidated Balance Sheets as of December 31, 2006 and 2007		F-3
Consolidated Statements of Income for each of the three years in the period ended December 31, 2007		F-4
Consolidated Statements of Stockholders’ Equity for each of the three years in the period ended December 31, 2007		F-5
Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2007		F-6
Notes to Consolidated Financial Statements		F-7

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of National Dentex Corporation:

In our opinion, the consolidated financial statements listed in the accompanying index appearing under Item 15(a)(1) present fairly, in all material respects, the financial position of National Dentex Corporation and its subsidiaries at December 31, 2007 and December 31, 2006, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2007, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2007, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on these financial statements and on the Company’s internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As discussed in Note 5 to the consolidated financial statements, during the year ended December 31, 2007, the Company changed the manner in which it accounts for uncertain tax positions.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/  PricewaterhouseCoopers LLP

Boston, MA

March 12, 2008

F-2

NATIONAL DENTEX CORPORATION

CONSOLIDATED BALANCE SHEETS

	December 31,			December 31,
	2006			2007
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	648,265		$	1,689,391
Accounts receivable:
Trade, less allowance of $290,000 in 2006 and $359,000 in 2007		17,022,130			16,073,716
Other		915,938			2,484,821
Inventories		7,212,975			7,354,062
Prepaid expenses		1,905,570			4,298,891
Deferred tax asset		1,347,387			964,892
Property held for sale		—			259,000
Total current assets		29,052,265			33,124,773
PROPERTY, PLANT AND EQUIPMENT:
Land and buildings		8,530,593			7,835,015
Leasehold and building improvements		13,428,314			16,202,649
Laboratory equipment		18,956,508			21,327,055
Furniture and fixtures		6,943,244			7,789,754
		47,858,659			53,154,473
Less — Accumulated depreciation and amortization		19,976,182			22,279,229
Net property, plant and equipment		27,882,477			30,875,244
OTHER ASSETS, net:
Goodwill		68,000,747			68,987,397
Trade names		9,032,102			8,998,123
Customer relationships		6,298,927			5,575,194
Non-competition agreements		2,225,431			1,743,867
Other assets		5,998,335			6,334,545
Total other assets		91,555,542			91,639,126
Total assets	$	148,490,284		$	155,639,143
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Revolving line of credit	$	1,343,228		$	4,547,101
Current portion of long-term debt		5,768,670			5,064,174
Accounts payable		4,344,704			5,810,303
Accrued liabilities:
Payroll and employee benefits		6,778,395			6,545,770
Current portion of deferred acquisition costs		1,517,694			1,278,861
Other accrued expenses		3,067,581			3,878,207
Total current liabilities		22,820,272			27,124,416
LONG-TERM LIABILITIES:
Long-term obligations		29,688,696			24,630,801
Deferred compensation		4,863,163			5,593,067
Other accrued expenses		1,581,494			961,453
Deferred tax liability		6,743,027			6,137,143
Total long-term liabilities		42,876,380			37,322,464
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $.01 par value
Authorized — 500,000 shares
None issued and outstanding		—			—
Common stock, $.01 par value
Authorized — 8,000,000 shares
Issued and Outstanding — 5,509,412 shares at December 31, 2006 and 5,582,119 shares at December 31, 2007		55,094			55,821
Paid-in capital		17,296,170			18,501,175
Retained earnings		65,564,279			72,189,938
Other comprehensive income		(121,911	)		445,329
Total stockholders’ equity		82,793,632			91,192,263
Total liabilities and stockholders’ equity	$	148,490,284		$	155,639,143

The accompanying notes are an integral part of these consolidated financial statements.

F-3

NATIONAL DENTEX CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

	Years Ended
	December 31,		December 31,		December 31,
	2005		2006		2007
Net sales	$	135,842,674	$	150,107,407	$	170,360,629
Cost of goods sold		78,380,380		88,269,509		97,738,785
Gross profit		57,462,294		61,837,898		72,621,844
Selling, general and administrative expenses		44,728,227		50,096,653		58,561,368
Operating income		12,734,067		11,741,245		14,060,476
Other expense		646,436		786,292		771,660
Interest expense		665,108		1,522,778		2,802,944
Income before provision for income taxes		11,422,523		9,432,175		10,485,872
Provision for income taxes		4,333,705		3,669,116		3,860,213
Net income	$	7,088,818	$	5,763,059	$	6,625,659
Net income per share — basic	$	1.33	$	1.05	$	1.20
Net income per share — diluted	$	1.27	$	1.01	$	1.17
Weighted average shares outstanding — basic		5,333,597		5,484,741		5,540,496
Weighted average shares outstanding — diluted		5,601,441		5,732,106		5,665,042

COMPREHENSIVE INCOME

	Years Ended
	December 31,		December 31,			December 31,
	2005		2006			2007
Net income	$	7,088,818	$	5,763,059		$	6,625,659
Foreign currency translation adjustments		—		(121,911	)		567,240
Total comprehensive income	$	7,088,818	$	5,641,148		$	7,192,899

The accompanying notes are an integral part of these consolidated financial statements.

F-4

NATIONAL DENTEX CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

	Common Stock									Cumulative
	Number of		$.01 Par		Paid-in		Retained			Translation
	Shares		Value		Capital		Earnings			Adjustment			Total
BALANCE, December 31, 2004		5,263,798	$	52,638	$	13,502,786	$	53,327,961			—		$	66,883,385
Issuance of 122,341 shares of common stock under the stock option plans		122,341		1,223		1,508,274								1,509,497
Issuance of 21,526 shares of common stock under the employee stock purchase program		21,526		215		332,832								333,047
Tax benefit associated with exercise of stock options						187,362								187,362
Net income								7,088,818						7,088,818
Issuance of 3,798 shares of common stock as director’s fees		3,798		38		71,934								71,972
BALANCE, December 31, 2005		5,411,463		54,114		15,603,188		60,416,779			—			76,074,081
Cumulative effect of SAB 108 adjustment (see Note 2)								(615,559	)					(615,559	)
Issuance of 71,567 shares of common stock under the stock option plans		71,567		716		939,227								939,943
Issuance of 25,318 shares of common stock under the employee stock purchase program		25,318		253		432,377								432,630
Tax benefit associated with exercise of stock options						96,105								96,105
Net income								5,763,059						5,763,059
Issuance of 1,064 shares of common stock as director’s fees		1,064		11		23,983								23,994
Stock compensation expense						201,290								201,290
Cumulative translation adjustment											(121,911	)		(121,911	)
BALANCE, December 31, 2006		5,509,412		55,094		17,296,170		65,564,279			(121,911	)		82,793,632
Issuance of 42,450 shares of common stock under the stock option plans		42,450		425		567,407								567,832
Issuance of 24,030 shares of common stock under the employee stock purchase program		24,030		240		295,325								295,565
Tax benefit associated with exercise of stock options						15,859								15,859
Net income								6,625,659						6,625,659
Issuance of 6,227 shares of common stock as director’s fees		6,227		62		165,302								165,364
Stock compensation expense						161,112								161,112
Cumulative translation adjustment											567,240			567,240
BALANCE, December 31, 2007		5,582,119	$	55,821	$	18,501,175	$	72,189,938		$	445,329		$	91,192,263

The accompanying notes are an integral part of these consolidated financial statements.

F-5

NATIONAL DENTEX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Years Ended
	December 31,			December 31,			December 31,
	2005			2006			2007
Cash flows from operating activities:
Net income	$	7,088,818		$	5,763,059		$	6,625,659
Adjustments to reconcile net income to net cash provided by operating activities, net of effects of acquisitions:
Depreciation and amortization		3,939,664			4,814,580			5,338,432
Loss (gain) on disposal of property, plant and equipment		105,398			(329,215	)		150,109
Benefit for deferred income taxes		(487,414	)		(1,379,347	)		(265,149	)
Impairment of long-lived assets		10,000			207,847			94,000
Tax benefit associated with exercise of stock options		187,362			96,105			15,859
Provision for bad debts		163,134			30,702			151,330
Losses on write-down of inventories		36,399			162,711			107,791
Stock-based compensation expense		71,972			225,284			326,477
Other non-cash items		—			(117,870	)		489,375
Changes in operating assets and liabilities, net of effects of acquisitions:
Increase in accounts receivable		(462,076	)		(479,582	)		(701,142	)
Increase in inventories		(146,854	)		(250,830	)		(226,117	)
(Increase) decrease in prepaid expenses		(602,853	)		1,269,889			(2,363,317	)
Decrease (increase) in other assets		34,596			3,660			(19,635	)
Increase in accounts payable and accrued liabilities		2,819,403			1,071,767			2,828,757
Net cash provided by operating activities		12,757,549			11,088,760			12,552,429
Cash flows from investing activities:
Payment for acquisitions, net of cash acquired		(23,456,720	)		(21,402,927	)		—
Payment of deferred purchase price		(1,575,780	)		(3,205,241	)		(2,158,880	)
Premiums paid for life insurance policies		(504,425	)		(498,856	)		(339,921	)
Additions to property, plant and equipment		(7,578,413	)		(4,899,460	)		(7,535,578	)
Dispositions of property, plant, and equipment		—			920,333			183,373
Net cash used in investing activities		(33,115,338	)		(29,086,151	)		(9,851,006	)
Cash flows from financing activities:
Borrowings of revolving line of credit		—			1,343,228			55,370,014
Repayments of revolving line of credit		(2,000,000	)		—			(52,166,141	)
Borrowings of long-term debt		19,884,346			19,625,000			—
Repayments of long-term debt		(1,183,592	)		(4,092,355	)		(5,775,105	)
Net proceeds from issuance of common stock		1,842,544			1,372,573			863,396
Net cash provided (used) by financing activities		18,543,298			18,248,446			(1,707,836	)
Effect of Exchange rate changes on cash		—			(4,041	)		47,539
Net (decrease) increase in cash and cash equivalents		(1,814,491	)		247,014			1,041,126
Cash and cash equivalents at beginning of period		2,215,742			401,251			648,265
Cash and cash equivalents at end of period	$	401,251		$	648,265		$	1,689,391
Supplemental disclosures of cash flow information:
Interest paid (net of capitalized interest of $109,000 in 2005, $18,000 in 2006 and $37,000 in 2007)	$	689,118		$	1,647,972		$	2,853,706
Income taxes paid	$	4,289,112		$	4,468,811		$	5,792,166
Supplemental schedule of non-cash investing and financing activities:
The Company purchased the operations of certain dental laboratories in 2005 and 2006. In connection with these acquisitions, liabilities were assumed as follows:
Fair value of assets acquired including acquired cash	$	32,083,000		$	28,821,000		$	—
Cash purchase price		(24,582,000	)		(21,725,000	)		—
Deferred purchase price at date of acquisition		(2,444,000	)		(967,000	)		—
Liabilities assumed	$	5,057,000		$	6,129,000		$	—

F-6

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2007

(1)   Organization

National Dentex Corporation (the “Company”) owns and operates 41 full-service dental laboratories and seven branch laboratories in 31 states throughout the United States and one Canadian province as of December 31, 2007. Working from dentists’ work orders, the Company’s dental laboratories custom design and fabricate dentures, crowns and fixed bridges, and other dental prosthetic appliances.

(2)   Summary of Significant Accounting Policies

Principles of Consolidation

The Company follows the guidance established in FASB Interpretation No. 46, “Consolidation of Variable Interest Entities”, in presenting the consolidated financial statements. Acquisitions are reflected from the date acquired by the Company (see Note 3) to December 31, 2007. All significant inter-company balances and transactions have been eliminated in consolidation.

Revenue Recognition

Revenue is recognized upon transfer of title and risk of loss, generally as the dentists’ orders are shipped. The Company records shipping and handling fees charged to customers as revenues in accordance with EITF 00-10 “Accounting for Shipping and Handling Fees and Costs”. Shipping and handling costs totaling approximately $10,852,000, $13,365,000 and $15,617,000 for the years ended December 31, 2005, 2006 and 2007, respectively, are included in selling, general and administrative expense.

Staff Accounting Bulletin No. 108

In September 2006, the SEC released SAB 108, “Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements” (“SAB 108”). SAB 108 permits the Company to adjust for the cumulative effect of misstatements related to prior years, previously deemed to be immaterial, in the carrying amount of assets and liabilities as of the beginning of the current fiscal year, with an offsetting adjustment to the opening balance of retained earnings in the year of adoption. SAB 108 also requires the adjustment of any prior quarterly financial statements in future SEC filings within the fiscal year of adoption for the effects of such misstatements on the quarters when the information is next presented. This adjustment does not require reports previously filed with the SEC to be amended. In addition, registrants are permitted to utilize SAB 108 treatment for errors that had not been previously identified in prior periods.

In the fourth quarter of 2006, management identified an error in the accounting for the Company’s Supplemental Executive Retirement Plans. A component of these plans is the recognition of compensation expense for the eventual payment to the recipient of the retirement benefit. Historically, the Company had recognized this expense over the period between the inception of the individual agreement to the recipient’s anticipated retirement date, and not over the vesting period, which vary up to a maximum of ten years. Generally Accepted Accounting Principles (“GAAP”) requires compensation expense for these arrangements to be recognized over the vesting period. The Company reviewed all agreements and recalculated the correct deferred compensation expense for all affected years, specifically 1995 through 2006, and compared the results to amounts historically recorded. Based upon that review, the Company concluded the errors to be immaterial to all previously issued financial statements under the “rollover method”, the method previously utilized by the Company to evaluate accounting errors. However, the impact of correcting the accumulated error to the 2006 financial statements was material. Accordingly, the Company has applied SAB 108 and adjusted beginning retained earnings for fiscal 2006, net of the related tax effects, in the accompanying consolidated financial statements.

F-7

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

As a result of the error described above, at January 1, 2006, deferred compensation liabilities were increased by $1,018,000 and the Company’s deferred tax asset was increased by $402,000 which resulted in a net decrease to stockholder’s equity of $616,000.

Goodwill and Other Indefinite-Lived Intangible Assets Not Subject to Amortization

In accordance with Statement of Financial Accounting Standards (“SFAS”) No. 142, goodwill amortization ceased on December 31, 2001. The Company continually evaluates whether events and circumstances have occurred that indicate that the value of goodwill has been impaired. In accordance with SFAS No. 142, goodwill is evaluated for possible impairment on an annual basis, based on a two-step process. The first step is to compare the fair value of the reporting unit to its carrying amount to determine if there is potential impairment. The second step, used to measure the amount of impairment loss, compares the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. In accordance with SFAS No. 142, the reporting unit is an operating segment or one level below an operating segment (referred to as a component). The Company has determined that the individual laboratories are reporting units. The Company determines fair value using factors based on revenue and operating margins. In the second quarters of 2005, 2006 and 2007, the Company completed the impairment testing and determined that no impairment existed.

Additionally, the Company also recognizes the existence of value in trade names acquired in business combinations and believes the useful life of this intangible to be indefinite based on a long history of utilizing the laboratory trade name. Accordingly, trade names are also evaluated for impairment on an annual basis using a single step method in accordance with SFAS No. 142. Impairment charges related to trade names are recognized when the fair value is less than the carrying value of the asset. Impairment charges related to trade names were recorded in the amount of $10,000, $47,000 and $94,000 for the years ended December 31, 2005, 2006 and 2007, respectively. Trade name impairment charges generally result from a decline in forecasted revenue at specific laboratories in comparison to revenue forecasts used in previous valuation calculations.

Intangible Assets Subject to Amortization

The Company follows the applicable accounting pronouncements — specifically SFAS No. 141 Business Combinations and Emerging Issues Task Force Abstract 02-17 Recognition of Customer Relationship Intangible Assets Acquired in a Business Combination in accounting for purchase business combinations. Non-competition agreements and customer relationship intangibles arising from dental laboratory acquisitions are amortized over their useful lives. The acquisition date fair value of non-competition agreements are deferred and amortized over their economic useful lives, in accordance with the terms of the agreements, over 2 to 15 years. The acquisition date fair value associated with acquired customer relationships are amortized over their estimated useful life, generally ranging over 9 to 12 years.

Advertising and Promotional Costs

Advertising, promotional and marketing costs are charged to earnings in the period in which they are incurred, in accordance with AICPA Statement of Position (SOP) 93-7, “Reporting on Advertising Costs.” These costs were approximately $1,252,000, $1,512,000 and $2,625,000 for the years ended December 31, 2005, 2006 and 2007, respectively.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with maturities of 90 days or less to be cash equivalents. At certain times the Company may have cash investments including overnight repurchase agreements with financial institutions in excess of the $100,000 insured limit of the Federal Deposit Insurance Corporation.

F-8

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are recorded at the invoiced amount. Service charges are assessed on balances 60 days past due. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company determines the allowance based on historical write-off experience. Past due balances over 90 days and over a specified amount are also reviewed individually for collectability. Account balances are charged off against the allowance when the Company determines it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to its customers.

Receivables consist of the following at December 31, 2006 and 2007:

	2006			2007
Trade	$	17,312,122		$	16,432,268
Allowance for doubtful accounts		(289,992	)		(358,552	)
Employee		74,822			85,850
Income Taxes		—			1,618,647
Other		841,116			780,324
Total Receivables	$	17,938,068		$	18,558,537

Following are the changes in the allowance for doubtful accounts during the years ended December 31, 2005, 2006 and 2007:

	Balance at		Charged to				Acquired in		Balance at
	Beginning		Costs and				Purchase Business		End of
	of Period		Expenses		Write-offs		Combinations		Period
Allowance for Doubtful Accounts:
December 31, 2005	$	181,181		163,134		138,534		94,000		299,781
December 31, 2006		299,781		30,702		94,224		53,733		289,992
December 31, 2007		289,992		151,330		82,770		—		358,552

Inventories

Inventories consist of the following:

	December 31, 2006		December 31, 2007
Raw Materials	$	5,853,793	$	5,941,931
Work in Process		1,112,467		1,160,686
Finished Goods		246,715		251,445
	$	7,212,975	$	7,354,062

Inventories are stated at the lower of cost (first-in, first-out) or market. Work in process represents an estimate of the value of specific orders in production yet incomplete at period end. Finished goods consist of completed orders that were shipped to customers immediately subsequent to period end.

F-9

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the following estimated depreciable lives:

Buildings	25 years
Furniture and fixtures	5 - 10 years
Laboratory equipment	5 - 20 years
Computer equipment	3 - 5 years

Leasehold improvements are amortized over the lesser of the assets’ estimated useful lives or the lease terms.

Gains and losses are recognized upon the disposal of property and equipment, and the related accumulated depreciation and amortization are removed from the accounts. Maintenance, repairs and betterments that do not enhance the value of or increase the life of the assets are charged to operations as incurred. The Company follows SFAS No. 34 “Capitalization of Interest Cost” (“SFAS No. 34”). Under SFAS No. 34, interest costs, if incurred, should be capitalized as part of the cost of acquiring or constructing qualifying assets. The Company had two qualifying assets which required a period of time to make ready for their intended use. Capitalized interest which is classified as Leasehold and Building Improvements totaled approximately $109,000, $18,000 and $37,000 for the years ended December 31, 2005, 2006 and 2007, respectively.

Depreciation expense totaled approximately $2,372,000, $3,135,000 and $4,055,000 for the years ended December 31, 2005, 2006 and 2007, respectively.

Impairment of Long-Lived Assets

At each balance sheet date, management evaluates the recoverability of the long-lived assets, including property and equipment and intangible assets, using certain financial indicators, such as historical and future ability to generate income from operations. The Company’s policy is to assess long-lived asset impairment in the period when it is determined that the carrying amount of the asset may not be recoverable. The determination is based on an evaluation of such factors as the occurrence of a significant event, a significant change in the environment in which the business operates or if the expected future undiscounted cash flows become less than the carrying amount of the asset.

Cash Surrender of Life Insurance

Life insurance policies, which are presented as other assets, are recorded at their net realizable value, which approximates the surrender value of the policy.

Income Taxes

The Company follows SFAS No. 109, “Accounting for Income Taxes”. Under SFAS No. 109, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. The amount of deferred tax asset or liability is based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

The Company also follows FASB issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes-an Interpretation of FASB Statement No. 109”, (“FIN 48”).” FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The minimum threshold is defined in FIN 48 as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or

F-10

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

Earnings per Share

In accordance with the disclosure requirements of SFAS No. 128, “Earnings per Share,” basic earnings per share is computed by dividing net income by the weighted average number of shares outstanding and diluted earnings per share reflects the dilutive effect of potential common shares. The weighted average number of shares outstanding, the dilutive effects of outstanding stock options and the shares under option plans that were anti-dilutive for the years ended December 31, 2005, 2006 and 2007 are as follows:

	Years Ended December 31,
	2005		2006		2007
Weighted average number of shares used in basic earnings per share calculation		5,333,597		5,484,741		5,540,496
Incremental shares under option and employee stock purchase plans		267,844		247,365		124,546
Weighed average number of shares used in diluted earnings per share calculation		5,601,441		5,732,106		5,665,042
Shares under option plans excluded in computation of diluted earnings per share due to anti-dilutive effects		NONE		1,927		1,215

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Disclosures about the Fair Value of Financial Instruments

The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, accounts payable, and current and long-term liabilities. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The carrying amount of the long-term liabilities also approximates their fair value, based on rates available to the Company for debt with similar terms and remaining maturities.

Comprehensive Income

SFAS No. 130, “Reporting Comprehensive Income,” requires disclosure of all components of comprehensive income on an annual and interim basis. Comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s total comprehensive income was as follows for the periods presented:

	Year Ended December 31,
	2005		2006			2007
Net income	$	7,088,818	$	5,763,059		$	6,625,659
Foreign currency translation adjustments		—		(121,911	)		567,240
Total comprehensive income	$	7,088,818	$	5,641,148		$	7,192,899

F-11

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Accumulated other comprehensive (loss), income at December 31, 2006 and 2007 of ($121,911) and $445,329, respectively, as presented in the equity section of the consolidated balance sheet is entirely attributable to accumulated foreign currency translation adjustments.

Disclosures about Segments of an Enterprise

SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information,” establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. SFAS No. 131 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate financial information is available for the evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance.

In March 2005, the Company acquired Green Dental Laboratories, Inc. of Heber Springs, Arkansas. In October 2006, the Company acquired Keller Group, Incorporated, a privately-held dental laboratory business with production facilities in both St. Louis, Missouri and Louisville, Kentucky. In accordance with SFAS 131, the Company identified Green and Keller as separate operating segments that do not meet the aggregation criteria of SFAS 131. As a result, the Company has three reportable segments. The accounting policies of these segments are consistent with those described for the consolidated financial statements in the summary of significant accounting policies.

Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS No. 157”), “Fair Value Measurements.” Among other requirements, SFAS 157 defines fair value and establishes a framework for measuring fair value and also expands disclosure about the use of fair value to measure assets and liabilities. SFAS 157 prescribes a single definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. SFAS 157 is effective beginning the first fiscal year that begins after November 15, 2007. However, in January 2008, the FASB issued FASB Staff Position FAS 157-b, “Effective Date of FASB Statement No. 157” (‘‘FSP FAS 157-b”). This FSP permits entities to elect to defer the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company has elected to defer the adoption of SFAS No. 157 for those assets and liabilities included in FSP FAS 157-b. The Company believes the adoption of SFAS No. 157 will not have a material impact on its financial position and results of operations.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities”, including an amendment of FASB Statement No. 115 (“SFAS No. 159”). SFAS No. 159 permits entities to choose, at specified election dates, to measure eligible items at fair value (the “fair value option”). A business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting period. This accounting standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company believes the adoption of SFAS No. 159 will not have a material impact on its financial position and results of operations.

In December 2007, the FASB issued FAS No. 141 (Revised 2007), “Business Combinations” (“FAS 141(R)”). FAS 141(R) establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements, the identifiable assets acquired, the liabilities assumed, and any non-controlling interest in the acquiree. The statement also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of business combinations. FAS 141 (R) is effective on a prospective basis for financial statements issued for fiscal years beginning after December 15, 2008.

F-12

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Accordingly, any business combination the Company enters into after December 31, 2008 will be subject to this new standard.

(3)   Acquisitions

The Company’s acquisition strategy is to consolidate within the dental laboratory industry and use its financial and operational synergies to create a competitive advantage. Certain factors, such as the laboratory’s assembled workforce, technical skills, and value as a going concern result in the recognition of goodwill.

In connection with certain acquisition agreements, the Company has incurred certain contractual obligations associated with deferred purchase price payments, which are not contingent on any future actions or performance measures. These deferred payments are recorded as a liability upon consummation of the acquisition and are included in the acquisition purchase price. Also, certain acquisition agreements contain provisions which require additional purchase price payments, contingent upon certain specified events, generally earnings targets. These contingent payments are recorded as an increase to goodwill upon the resolution of the contingency.

In addition, in certain transactions, the Company executes non-compete agreements with the former owners and other key employees. The fair value of these agreements is recognized in purchase accounting as an identifiable intangible asset and is amortized over the estimated economic life of the agreement. All acquisitions have been reflected in the accompanying consolidated financial statements from the date of acquisition and have been accounted for as purchase business combinations in accordance with SFAS No. 141, “Business Combinations” (“FAS 141”). Purchase price is allocated to acquired assets and liabilities based on estimates of their related fair values. Subsequent to the purchase date, the Company continues to evaluate the initial purchase price allocations for the acquisitions and will adjust the allocations as additional information about the fair market values of the assets and liabilities of the businesses previously identified becomes known. These purchase price adjustments can occur for up to one year from the acquisition date.

During 2006, the Company acquired the following dental laboratory operations:

Acquisition	Form of Acquisition	Location	Period Acquired
Impact Dental Laboratory Limited	All Outstanding Capital Stock	Ottawa, ON Canada	October, 2006
Keller Group, Incorporated	All Outstanding Capital Stock	St Louis, MO	October, 2006

Keller reported sales in excess of $17,000,000 in 2005. The cost of the acquisition of Keller, net of cash acquired, was approximately $19,374,000. Impact reported sales in excess of $3,500,000 in 2005. The cost of the acquisition of Impact, net of cash acquired, was approximately $2,996,000.

F-13

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The total purchase price has been allocated to the acquired assets and liabilities based on estimates of their related fair values. The total purchase price was allocated as follows as of December 31, 2006:

	Year Ended December 31, 2006
	Keller			Impact Dental
	Group,			Laboratory			Total
	Incorporated			Limited			Acquired
Total Purchase Price	$	19,692,000		$	3,000,000		$	22,692,000
Less Fair Market Values Assigned to
Tangible Assets and Liabilities:
Cash		318,000			4,000			322,000
Accounts receivable		2,008,000			418,000			2,426,000
Inventories		292,000			133,000			425,000
Property, plant and equipment		1,571,000			422,000			1,993,000
Other assets		122,000			49,000			171,000
Accounts payable		(546,000	)		(151,000	)		(697,000	)
Accrued and other liabilities		(3,807,000	)		(520,000	)		(4,327,000	)
Assumed debt		(1,034,000	)		(71,000	)		(1,105,000	)
Less Fair Market Values Assigned to
Intangible Assets:
Customer relationships		1,000,000			294,000			1,294,000
Trade names		3,100,000			348,000			3,448,000
Non-compete agreements		500,000			50,000			550,000
Goodwill	$	16,168,000		$	2,024,000		$	18,192,000

Certain acquisition agreements contain provisions for additional payments based on earnings goals. There were no contingent obligations associated with these 2006 acquisitions. Payments are recorded as goodwill when they are determinable. Acquired goodwill in certain situations may be tax deductible over a fifteen-year period, as allowed under Internal Revenue Service Code Section 197. However, acquired goodwill for those acquisitions completed in 2006 is not tax deductible.

The following unaudited pro forma operating results of the Company assume the acquisitions of 2006 had been made as of January 1, 2006. Such information includes adjustments to reflect additional depreciation, non-compete and customer relationship amortization and interest expense, and is not necessarily indicative of what the results of operations would actually have been or of the results of operations in future periods.

	Years Ended
	December 31, 2006		December 31, 2007
Net sales	$	168,019,000	$	170,361,000
Net income		6,184,000		6,626,000
Net income per share:
Basic	$	1.13	$	1.20
Diluted	$	1.08	$	1.17

F-14

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(4)   Goodwill and Other Intangible Assets

The changes in the carrying amount of goodwill for the years ended December 31, 2006 and 2007 are as follows:

	Years Ended
	December 31, 2006			December 31, 2007
Balance as of January 1	$	48,242,000		$	68,001,000
Goodwill acquired during the year		18,192,000			—
Adjustments related to contingent consideration		1,644,000			667,000
Adjustments related to the finalization of preliminary purchase estimates		—			(31,000	)
Effects of exchange rate changes		(77,000	)		350,000
Balance as of December 31	$	68,001,000		$	68,987,000

The changes in the consolidated goodwill balance for 2006 and 2007 as summarized in the above table relate to the NDX Laboratories reportable segment except for the goodwill recognized in connection with Keller (acquired in 2006) as further described in Note 3. As of December 31, 2007, the goodwill balances for the Green, Keller and NDX Laboratories operating segments are $15,208,000, $16,143,000 and $37,636,000, respectively.

The Company’s contingent laboratory purchase price liabilities subject to acquisition agreements that are tied to earnings performance, generally over a three year period, as defined in the purchase agreements, are approximately $300,000 as of December 31, 2007. As the contingency is resolved, the payments are recorded as goodwill. In connection with dental laboratory acquisitions, the Company has identified certain other intangible assets including trade names, customer relationships and non-competition agreements.

Trade Names

Trade names as acquired are valued using a quantification of the income generated based on the recognition afforded by the trade name in the marketplace, using the relief-from-royalty valuation approach. Company practice is to use existing and acquired trade names in perpetuity, and consequently they have been treated as indefinite-lived intangibles. While these assets are not subject to amortization, they are tested for impairment on an annual basis in accordance with SFAS No. 142. The Company uses the relief-from-royalty valuation approach at each fiscal year end to determine the value of the asset. Trade name impairment charges resulted from a decline in forecasted revenue at specific laboratories in comparison to revenue forecasts used in previous valuation calculations. The Company recorded impairment charges of $47,000 and $94,000 in the fourth quarter of 2006 and 2007, respectively. Impairment charges are a component of selling, general and administrative expense.

The changes in the carrying amount of trade names for the years ended December 31, 2006 and 2007 are as follows:

	Years Ended
	December 31, 2006			December 31, 2007
Beginning of year	$	5,644,000		$	9,032,000
Trade names acquired during the year		3,448,000			—
Effects of exchange rate changes		(13,000	)		60,000
Trade Names		9,079,000			9,092,000
Less: Charged to Impairment Expense		(47,000	)		(94,000	)
Trade Names — End of year	$	9,032,000		$	8,998,000

F-15

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Customer Relationships

Acquired dental laboratories have customer relationships in place with dentists within their market areas. Based on the criteria of EITF 02-17, the Company recognizes customer relationship assets when established relationships exist with customers through contract or other contractual relationships such as purchase orders or sales orders. Customer relationships are valued based on an analysis of revenue and customer attrition data and amortized over their useful life. The weighted-average amortization period for acquisitions completed in 2005 and 2006 was 11.4 years and 12.0 years, respectively. The amounts assigned to customer relationships are amortized on a straight-line basis over their useful lives. The Company has determined that the straight-line method is appropriate based on an analysis of customer attrition statistics.

	Years Ended
	December 31, 2006			December 31, 2007
Beginning of year	$	6,663,000		$	7,945,000
Customer relationships acquired during the year		1,294,000			—
Effects of exchange rate changes		(12,000	)		48,000
Customer Relationships, Gross		7,945,000			7,993,000
Less: Accumulated amortization		(1,646,000	)		(2,418,000	)
Customer Relationships, Net — End of year	$	6,299,000		$	5,575,000

Amortization expense associated with customer relationships totaled approximately $599,000, $702,000 and $771,000 for the years ended December 31, 2005, 2006 and 2007, respectively, and is recorded as operating expenses. Future amortization expense of the current customer relationship balance will be approximately:

2008	$	771,000
2009		771,000
2010		771,000
2011		771,000
2012		701,000
Thereafter		1,790,000
	$	5,575,000

Non-competition Agreements

In connection with acquisitions, the Company has executed non-compete agreements with certain individuals, ranging over periods of 2 to 15 years. The weighted-average amortization period, which is based on the estimated useful life of the agreement, for acquisitions completed in 2005 and 2006 was 10.7 years and 9.5 years, respectively. The amounts assigned to non-competition agreements are amortized on a straight-line basis over the economic useful life of the agreement, and are recorded as operating expenses.

	Years Ended
	December 31,			December 31,
	2006			2007
Beginning of year	$	9,998,000		$	10,546,000
Non-competition agreements acquired during the year		550,000			—
Non-competition agreements, gross		10,548,000			10,546,000
Less: Accumulated amortization		(8,321,000	)		(8,809,000	)
Effects of exchange rate changes		(2,000	)		7,000
Non-competition agreements, net	$	2,225,000		$	1,744,000

F-16

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Amortization expense associated with non-competition agreements totaled approximately $945,000, $939,000 and $489,000 for the years ended December 31, 2005, 2006 and 2007, respectively.

Future amortization expense of non-competition agreements will be approximately:

2008	$	296,000
2009		274,000
2010		266,000
2011		225,000
2012		170,000
Thereafter		513,000
	$	1,744,000

(5)   Income Taxes

The following is a summary of the provision (benefit) for income taxes:

	Years Ended
	December 31,			December 31,			December 31,
	2005			2006			2007
Federal —
Current	$	3,797,588		$	4,229,525		$	2,985,255
Deferred		(253,942	)		(1,220,661	)		(189,842	)
		3,543,646			3,008,864			2,795,413
State —
Current		838,069			818,938			860,500
Deferred		(48,010	)		(158,686	)		(25,700	)
		790,059			660,252			834,800
Foreign —
Current		—			—			237,848
Deferred		—			—			(7,848	)
		—			—			230,000
	$	4,333,705		$	3,669,116		$	3,860,213

Deferred income taxes are comprised of the following at December 31, 2006 and 2007:

	2006			2007
Deferred Tax Assets:
Non-compete agreements	$	1,090,582		$	1,046,036
Other liabilities		2,449,479			2,703,010
Vacation benefits		685,282			714,177
Inventory basis differences		271,667			274,563
Receivables basis differences		15,442			11,873
Total deferred tax assets		4,512,452			4,749,659
Deferred Tax Liabilities:
Depreciation differences		(2,232,646	)		(2,220,792	)
Intangible amortization differences		(7,675,445	)		(7,701,118	)
Total deferred tax liabilities		(9,908,092	)		(9,921,910	)
Net deferred tax asset/liability	$	(5,395,640	)	$	(5,172,251	)

F-17

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Through December 31, 2007, the Company has not provided deferred income taxes on the undistributed earnings of its foreign subsidiary because such earnings are intended to be permanently reinvested outside the U.S. Determination of the potential deferred income tax liability on these undistributed earnings is not practicable. At December 31, 2007, the Company had $230,000 of undistributed earnings in its foreign subsidiary.

During 2005, the Company’s marginal federal tax rate increased from 34% to 35%, as a result of taxable income in excess of $10,000,000. Accordingly, deferred tax assets and liabilities have been adjusted in accordance with SFAS No. 109. The effect of this adjustment was an increase of approximately $129,000 to the 2005 tax expense.

A reconciliation between the provision for income taxes computed at statutory rates and the amount reflected in the accompanying statements of income is as follows:

	December 31,			December 31,			December 31,
	2005			2006			2007
Statutory federal income tax rate		35.0	%		35.0	%		35.0	%
State income tax, net of federal income tax benefit		4.6			4.6			4.9
Other		(1.7	)		(.7	)		(3.1	)
Effective income tax rate		37.9	%		38.9	%		36.8	%

The Company adopted the provisions of FIN 48 on January 1, 2007. At December 31, 2006 the Company had recorded $296,000 of unrecognized tax benefits and related interest and penalties of $51,000. This liability related to ongoing tax filing positions taken by the Company in its previously filed US Federal and State tax returns. In connection with the adoption of FIN 48, the Company determined this $347,000 met the FIN 48 recognition provisions and no material adjustments were required upon adoption. Interest and penalties, as appropriate, are recorded as a component of the Company’s tax liability and tax provision. Interest and penalties recorded for the year ended December 31, 2007 were approximately $51,000.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, exclusive of accrued interest and penalties of $51,000 at January 1, 2007 and $102,000 at December 31, 2007, is as follows:

Unrecognized tax benefits at January 1, 2007	$	296,000
Additions based on tax positions related to the current year		1,599,000
Additions for tax positions of prior years		138,000
Unrecognized tax benefits at December 31, 2007	$	2,033,000

These balances represent unrecognized tax benefits that would decrease the Company’s effective tax rate upon recognition. The Company believes that it is reasonably possible unrecognized tax benefits of $570,000 and accruals for interest and penalties of $102,000 will decrease in 2008 as a result in the lapse of the statute of limitations. Additionally, the Internal Revenue Service (“IRS”) commenced an examination of the Company’s U.S. income tax returns for 2003 through 2006 in the second quarter of 2007. As of December 31, 2007, the tax years that remain subject to examination by the IRS and other jurisdictions are 2002 to 2007.

(6)   Lines of Credit and Term Loan Facility

On August 9, 2005, the Company entered into an amended and restated financing agreement (the “Amended Agreement”) with Bank of America, N.A. (the “Bank”). The Amended Agreement included a revolving line of credit of $5,000,000, a revolving acquisition line of credit of $20,000,000 and a term loan facility of $20,000,000. The interest rate on both revolving lines of credit and the term loan was the prime rate or, at the Company’s option, LIBOR, a cost of funds rate or the Bank’s fixed rate plus a range of 1.25% to 2.25%, depending on the ratio of consolidated funded debt to consolidated “EBITDA”, as defined in the Amended Agreement. The Amended Agreement required monthly payments of principal, based on a seven year amortization schedule, with a final

F-18

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

payment due on the fifth anniversary of the Amended Agreement. The Amended Agreement required compliance with certain covenants, including the maintenance of specified net worth, income and other financial ratios.

In October 2006, the Company borrowed against its acquisition line of credit to finance the acquisition of Keller Group, Incorporated (“Keller”). In order to refinance the borrowings incurred for the Keller acquisition, the Company and the Bank executed a Second Amended and Restated Loan Agreement as of November 7, 2006 (the “Second Agreement”) comprised of uncollateralized senior credit facilities totaling $60,000,000. The Second Agreement amended and restated the Amended Agreement (a) to increase the term loan facility to an aggregate principal amount of $35,000,000 and used the proceeds of the increase in the term loan to repay the outstanding principal balance under the acquisition line of credit and (b) to adjust the allocation of availability under the lines of credit by increasing the revolving line of credit to $10,000,000 ($5,000,000 of which may be used for future acquisitions) and decreasing the acquisition line of credit from $20,000,000 to $15,000,000. The interest rate on both lines of credit and the term loan is now the prime rate or, at the Company’s option, LIBOR, a cost of funds rate or the Bank’s fixed rate, plus, in each case, a range of 1.25% to 3.00%, depending on the ratio of consolidated total funded debt to consolidated “EBITDA”, as each is defined in the Second Agreement. The term loan facility portion of the Second Agreement requires monthly interest payments and monthly payments of principal, based on a seven year amortization schedule, with a final payment due on the fifth anniversary of the Second Agreement. The acquisition line of credit and the first line of credit mature on the third anniversary of the Second Agreement. The Second Agreement requires compliance with certain covenants, including the maintenance of specified net worth, income and other financial ratios. The Second Agreement was amended effective June 30, 2007 to revise certain financial targets within these covenants.

As of December 31, 2007, $5,453,000 was available under the revolving line of credit and $15,000,000 was available under the acquisition line of credit.

	December 31,		December 31,
	2006		2007
Total long-term debt	$	35,458,000	$	29,695,000
Less: Current maturities		5,769,000		5,064,000
Long-term debt, less current portion	$	29,689,000	$	24,631,000

The table below reflects the contractual repayment terms associated with the existing Second Amended Agreement at December 31, 2007. The interest rate associated with the Company’s borrowings as of December 31, 2007 was 7.8%.

	Principal Due
Fiscal 2008		5,064,000
Fiscal 2009		5,044,000
Fiscal 2010		5,004,000
Fiscal 2011		14,583,000
Total	$	29,695,000

(7)   Benefit Plans

The Company has a qualified retirement plan under Internal Revenue Code Sections 401(a) and 401(k) (the “401(k) Plan”). The 401(k) Plan allows contributions of up to 10% of a participant’s salary, a portion of which is matched in cash by the Company. The Company contributes cash once a year, within 120 days after December 31, the 401(k) Plan’s year-end. All employees are eligible to participate in the 401(k) Plan after completing one year of service with the Company and the attainment of age 21. Participants are fully vested immediately in employee contributions and become fully vested in the Company’s matching contributions after six years of service or upon

F-19

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

attaining age 65. The Company has incurred charges to operations of approximately $668,000, $777,000 and $826,000 to match contributions for the years ended December 31, 2005, 2006 and 2007, respectively.

The Company has a cash incentive plan (the “Laboratory Plan”) for dental laboratory management and other designated key employees who could directly influence the financial performance of an individual dental laboratory. Eligibility is determined annually for each laboratory. Each participant is eligible to receive an amount based on the achievement of certain earnings levels and other performance metrics by the participant’s laboratory, as defined. The Company has incurred charges to operations of approximately $4,419,000, $4,081,000 and $3,872,000 for the years ended December 31, 2005, 2006 and 2007, respectively, under the Laboratory Plan.

The Company has an executive bonus plan (the “Executive Plan”) for key executives and management of the Company. Eligibility to participate in this plan is determined annually. Participants are eligible to receive a cash bonus, based on a percentage of salary, dependent upon the achievement of earnings targets, as defined. The bonus is distributed within 90 days after year-end. The Company has incurred aggregate charges to operations of approximately $575,000, $150,000 and $448,000, for the years ended December 31, 2005, 2006 and 2007, respectively, with respect to this plan.

The Company established a Supplemental Executive Retirement Plan (“SERP”) for certain key employees providing for annual benefits payable over a period of 10 years beginning at age 65 or date of retirement. Benefits are funded by life insurance contracts purchased by the Company. These benefits vest to the participating employees over periods of up to ten years. The charges to expense for the years ended December 31, 2005, 2006 and 2007, were approximately $483,000, $495,000 and $727,000, respectively and are recorded as accrued liabilities.

(8)   Commitments and Contingencies

Operating Leases

The Company is committed under various non-cancelable operating lease agreements covering its office space and dental laboratory facilities and certain equipment. Certain of these leases also require the Company to pay maintenance, repairs, insurance and related taxes. The total rental expense for the years ended December 31, 2005, 2006 and 2007 was approximately $3,943,000, $4,135,000 and $5,061,000 respectively. The approximate aggregate minimum lease commitments under these operating leases as of December 31, 2007 are as follows:

Year	Amount
2008		4,029,000
2009		3,473,000
2010		2,981,000
2011		2,669,000
2012		2,370,000
Thereafter		6,648,000
	$	22,170,000

Employment Contracts and Change-in-Control Arrangements

In April 1995, January 2001, May 2004, and October 2006 the Company entered into employment contracts and change-in-control arrangements with certain key executives. The initial term of these employment contracts is three years and the contracts by their terms renew automatically thereafter until termination by the Company or the executive. The change-in-control arrangements provide certain severance benefits in the event that the executive is terminated by the Company without cause or the executive terminates his employment contract for certain specified reasons.

F-20

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(9)  Stock Options and Employee Stock Purchase Plan

Stock Option Plans

In May 1992, the Company’s Board of Directors (the “Board”) adopted the 1992 Long-Term Incentive Plan (the “LTIP”). Under the LTIP, the Board may grant stock options, stock appreciation rights, restricted stock, deferred stock, stock purchase rights and other share-based payments to key employees, officers and directors of the Company. The Board amended the LTIP to increase the number of shares of common stock reserved for issuance under the plan from 225,000 to 352,500 (in August 1995), to 502,500 (in April 1997) and to 727,500 (in April 1998). As of May 2002, no additional options may be granted under this plan. These options vest over three years from date of grant with a maximum term of ten years.

The following summarizes the transactions of the Company’s LTIP for the years ended December 31, 2005, 2006 and 2007:

	2005					2006					2007
				Weighted Average					Weighted Average					Weighted Average
	Shares			Exercise Price		Shares			Exercise Price		Shares			Exercise Price
Outstanding at beginning of year		449,069		$	11.95		359,181		$	12.14		308,544		$	12.10
Granted		—			—		—			—		—			—
Exercised		(80,917	)		11.21		(45,592	)		12.35		(39,900	)		13.34
Canceled		(8,971	)		10.97		(5,045	)		12.78		(25,079	)		13.15
Outstanding at end of year		359,181		$	12.14		308,544		$	12.10		243,565		$	11.79
Exercisable at end of year		359,181		$	12.14		308,544		$	12.10		243,565		$	11.79
Weighted average fair value of options granted	$	—				$	—				$	—

	Options Outstanding						Options Exercisable
	Number		Weighted Average		Weighted Average		Number		Weighted Average
	Outstanding at		Remaining		Exercise Price		Exercisable		Exercise Price
Exercise Price Range	12/31/07		Contractual Life		per Share		at 12/31/07		Per Share
$8.17 to $10.00 per share		56,550		2.3	$	8.67		56,550	$	8.67
$10.17 to $11.17 per share		50,640		1.1		10.24		50,640		10.24
$13.50 to $16.59 per share		136,375		3.1		13.66		136,375		13.66
		243,565		2.5	$	11.79		243,565	$	11.79

In January 2001, the Company’s Board of Directors adopted the 2001 Stock Plan. Under this plan, the Board may grant share based payments to key employees, officers and directors of the Company. The Board reserved 450,000 shares of common stock for issuance under the Plan. In April 2004, the Board amended the 2001 Stock Plan to increase the number of shares of common stock reserved for issuance under the plan from 450,000 to 825,000. An aggregate of 392,057 shares remain available for future grants under this plan. Options under this plan to date vest over three years from date of grant with a maximum term of ten years.

F-21

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following summarizes the transactions of the Company’s 2001 Stock Plan for the years ended December 31, 2005, 2006 and 2007:

	2005					2006					2007
				Weighted Average					Weighted Average					Weighted Average
	Shares			Exercise Price		Shares			Exercise Price		Shares			Exercise Price
Outstanding at beginning of year		407,350		$	14.55		358,925		$	14.52		331,950		$	14.52
Granted		—			—		—			—		—			—
Exercised		(41,425	)		15.04		(25,975	)		14.52		(2,550	)		13.96
Canceled		(7,000	)		13.56		(1,000	)		13.37		(11,400	)		14.51
Outstanding at end of year		358,925		$	14.52		331,950		$	14.52		318,000		$	14.53
Exercisable at end of year		328,741		$	14.62		331,950		$	14.52		318,000		$	14.53
Weighted average fair value of options
granted	$	—				$	—				$	—

	Options Outstanding						Options Exercisable
	Number		Weighted Average		Weighted Average		Number		Weighted Average
	Outstanding at		Remaining		Exercise Price		Exercisable		Exercise Price
Exercise Price Range	12/31/07		Contractual Life		Per Share		at 12/31/07		Per Share
$13.37 to $13.37 per share		168,650		4.1	$	13.37		168,650	$	13.37
$13.93 to $16.45 per share		149,350		3.9		15.83		149,350		15.83
		318,000		4.0	$	14.53		318,000	$	14.53

Also, the Company has the 1992 Employees’ Stock Purchase Plan (the “Stock Purchase Plan”), as amended by the stockholders in May 2007, under which an aggregate of 450,000 shares of the Company’s common stock have been reserved. These shares may be purchased in the current plan year through a payroll deduction program, primarily at a price equal to 85% of the fair market value of the common stock on either April 1, 2007 or March 31, 2008, whichever is lower. Approximately 150,000 shares are available for future purchases as of December 31, 2007. The number of shares of common stock purchased through the Stock Purchase Plan for 2005, 2006 and 2007 were 21,526, 25,318, and 24,030 respectively.

(10)   Stock-Based Compensation

The Company adopted the provisions of Statement of Financial Accounting Standard No. 123 (Revised 2004) (“SFAS 123R”), Share Based Payments and Staff Accounting Bulletin No. 107 (“SAB 107”) on January 1, 2006. SFAS 123R requires the Company to measure and recognize in its consolidated statement of income the expense associated with all share-based payment awards made to employees and directors. The Company’s awards include stock options awards and shares issued under the terms of the Company’s Employee Stock Purchase Plan (“ESPP”). The estimated fair value of stock compensation cost is recognized over the employees’ or directors’ service vesting period. The Company implemented SFAS 123R using the modified prospective approach. All stock options issued prior to January 1, 2006 were fully vested upon implementation of SFAS 123R.

Prior to January 1, 2006, the Company accounted for share-based payments under APB Opinion No. 25, Accounting for Stock Issued to Employees (“APB 25”). Under APB 25 compensation cost was not recognized for options granted because the exercise price of options granted was equal to the market value of the Company’s common stock on the measurement date and the ESPP plan was deemed non-compensatory.

F-22

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

As a result of the adoption of FAS 123R, the accompanying consolidated statement of income for the years ended December 31, 2006 and 2007 include $153,000 and $161,000 of stock based compensation expense. Compensation cost is measured on the grant date of the option, which is the date the Company’s Board of Directors approves the granting of the option. Compensation cost on discounts associated with ESPP purchases is estimated on the date that share rights are granted. To measure the fair value of stock option grants, the Company utilizes the Black-Scholes option valuation method. The requisite service period for substantially all of the Company’s stock options is the explicit vesting period included in the terms of the stock option award. Accordingly, the Company estimates compensation expense based on the number of options it believes will ultimately vest, which includes an estimate of the number of options expected to be forfeited. The estimated fair value of stock option grants will be recognized on a straight line basis over the requisite service period of the award. The Company periodically reviews its estimate of forfeitures and revises the estimate as facts and circumstances warrant.

In April, 2001 the Company’s shareholders approved the 2001 Stock Plan (the “2001 Plan”), under which awards may be granted to key employees, officers and directors in the form of stock options. The Company’s shareholders approved an amendment to the 2001 Plan on May 16, 2006 to allow for the issuance of restricted stock and restricted stock units. The maximum number of shares or units that may be issued under the 2001 Plan, as amended, is 825,000, subject to a sub-limit of 82,500 shares for restricted stock awards and restricted stock unit awards. At December 31, 2007, options to purchase a total of 318,000 shares were outstanding and there were 392,057 shares available for grant under the 2001 Plan. The Company also has the 1992 Long Term Incentive Plan (the “LTIP”) under which similar stock options also were granted. At December 31, 2007, options to purchase a total of 243,565 shares were outstanding under the LTIP. No further awards will be made under the LTIP. Stock option awards granted under the 2001 Plan and the LTIP generally vest ratably over three years on the anniversary date of the grants and are exercisable generally over a period of ten years.

In 1992, shareholders approved the establishment of the ESPP commencing April 1, 1992. Upon enrollment, employees purchase shares of the Company’s common stock at the end of each plan year, through payroll deductions, at a discount of 15% of the lower of the market price on the date of grant or the date of exercise, as quoted on NASDAQ.

A summary of stock option activity and related information for the year ended December 31, 2007, and the year ended December 31, 2006 is as follows:

	LTIP Plan					2001 Plan
				Weighted-					Weighted-
	Shares			Average		Shares			Average
	Underlying			Exercise		Underlying			Exercise
	Options			Price		Options			Price
Outstanding December 31, 2005		359,181		$	12.14		358,925		$	14.52
Granted		—			—		—			—
Exercised		(45,592	)		12.35		(25,975	)		14.52
Forfeited		(5,045	)		12.78		(1,000	)		13.37
Outstanding December 31, 2006		308,544		$	12.10		331,950		$	14.52
Granted		—			—		—			—
Exercised		(39,900	)		13.34		(2,550	)		13.96
Forfeited		(25,079	)		13.15		(11,400	)		14.51
Outstanding December 31, 2007		243,565		$	11.79		318,000		$	14.53
Exercisable at end of period:		243,565		$	11.79		318,000		$	14.53

For the year ended December 31, 2007, the Company granted 6,001 shares of restricted stock and 6,003 restricted stock units as directors’ fees under the 2001 Plan, as amended in May 2006. For the year ended December 31, 2006, the Company granted 1,596 shares of restricted stock and 3,192 restricted stock units as

F-23

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

directors’ fees. The Company recorded stock-based compensation expense related to these shares and units of $165,365 and $72,000 for the years ended December 31, 2007 and 2006.

The following table summarizes restricted stock and restricted stock unit awards for the year ended December 31, 2007 and year ended December 31, 2006 as follows:

	Restricted Stock				Restricted Stock Units
			Weighted-Average				Weighted-Average
			Grant Date Fair				Grant Date Fair
	Number of Shares		Value		Number of Shares		Value
Nonvested December 31, 2005		—		—		—		—
Granted		1,596	$	22.55		3,192	$	22.55
Vested		—		—		—		—
Nonvested December 31, 2006		1,596	$	22.55		3,192	$	22.55
Granted		6,001	$	17.99		6,003	$	17.99
Vested		1,596	$	22.55		3,192	$	22.55
Nonvested December 31, 2007		6,001	$	17.99		6,003	$	17.99

As of December 31, 2007, there was $100,125 and $40,500 of total unrecognized compensation cost for restricted stock and restricted stock units, respectively, and no unrecognized compensation cost related to stock options. That cost will be recognized over a weighted average period of 12 months. As of December 31, 2006, there was $12,000 and $24,000 of total unrecognized compensation cost for restricted stock and restricted stock units, respectively, and no unrecognized compensation cost related to stock options. The total aggregate intrinsic value of share-based payments outstanding as of December 31, 2007 is $1,449,000. Aggregate intrinsic value is calculated by subtracting the exercise price of the option from the closing price of the Company’s common stock on December 31, 2007 multiplied by the number of shares per each option. In addition, the weighted average remaining contractual life of options outstanding as of December 31, 2007 is 3.2 years. The total intrinsic value of options exercised during the year ended December 31, 2007 was $108,000.

The following tables summarize the significant assumptions used to estimate stock compensation costs for the periods indicated:

	January 1-			April 1-
	March 31,			December 31,
	2007			2007
Weighted-Average Grant Date Fair Value	$	6.69		$	4.18
Risk-free interest rate		5.27	%		4.92	%
Expected Volatility		33.19	%		30.29	%
Expected Holding Period		1.0 Year			1.0 Year
Expected Forfeiture Rate		5.70	%		9.67	%
Expected Dividends		None			None

F-24

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

	January 1-			April 1-
	March 31,			December 31,
	2006			2006
Weighted-Average Grant Date Fair Value	$	4.41		$	6.69
Risk-free interest rate		1.61	%		5.27	%
Expected Volatility		26.77	%		33.19	%
Expected Holding Period		1.0 Year			1.0 Year
Expected Forfeiture Rate		5.70	%		5.70	%
Expected Dividends		None			None

The weighted average grant date fair value was calculated under the Black-Scholes option-pricing model. The risk free interest rate is based on the yield of U.S. Treasury securities that correspond to the expected holding period of the options. The Company reviewed the historic volatility of its common stock, and the implied volatility for at-the-money options to purchase shares of the Company’s common stock. Based on this data, the Company uses the 1-year historic volatility of the Company’s common stock and the average implied volatility of at-the-money options. The 1-year historical volatility period was selected since that period corresponds with the expected holding period. The expected forfeiture rate was determined based on the historical ESPP forfeiture data. The dividend yield was based on the Company’s expected dividend rate.

Prior to adopting FAS 123R, the Company had disclosed the pro forma effects of stock-based compensation in accordance with FAS 148 “Accounting for Stock-Based Compensation — Transition and Disclosure — an amendment of FASB Statement No. 123”. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation, to stock-based employee compensation during the year ended December 31, 2005, as required by FAS 148.

	Year Ended
	December 31, 2005
Net income, as reported:	$	7,088,818
Add: Stock-based employee compensation expense included in reported net income
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects		80,149
Pro forma net income		7,008,669
Earnings per share: As reported, basic	$	1.33
Pro forma, basic		1.31
As reported, diluted		1.27
Pro forma, diluted		1.25

There were no options granted during the year ended December 31, 2005. The following table summarizes the significant assumptions used to estimate stock compensation using the Black-Scholes option-pricing model costs for the year period ended December 31, 2005.

	January 1-December 31, 2005
Weighted-Average Grant Date Fair Value	$	4.41
Risk-free interest rate		1.61	%
Expected Volatility		26.77	%
Expected Holding Period		1.0 Year
Expected Dividends		None

F-25

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

(11)   Segment Information

The Company follows Statement of Financial Accounting Standards No. 131 (“SFAS 131”), “Disclosures about Segments of an Enterprise and Related Information”. SFAS 131 establishes standards for disclosing information about reportable segments in financial statements. Laboratory operating income includes the direct profits generated by laboratories owned by the Company and excludes general and administrative expenses of the Company’s corporate location including amortization expenses associated with the Company’s intangible assets as well as interest expense.

In March 2005, the Company acquired Green Dental Laboratories, Inc. of Heber Springs, Arkansas. The Company identified Green as a separate operating segment since it met the quantitative thresholds of SFAS 131. In October 2006, the Company acquired Keller Group, Incorporated, a privately-held dental laboratory business with production facilities in both St. Louis, Missouri and Louisville, Kentucky. The Company has also identified Keller as a separate operating segment as it meets the quantitative thresholds of SFAS 131. As a result, the Company has three reportable segments. The accounting policies of this segment are consistent with those described for the consolidated financial statements in the summary of significant accounting policies.

F-26

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The following table sets forth information about the Company’s reportable segments for the years ended December 31, 2007, 2006 and 2005. Prior to the fourth quarter of 2006 the Company had two reportable segments and prior to 2005 the Company had only one reportable segment.

	Year Ended		Year Ended		Year Ended
	December 31,		December 31,		December 31,
	2005		2006		2007
Revenue:
NDX Laboratories	$	121,370,004	$	126,543,054	$	127,388,588
Green Dental Laboratory		14,513,115		18,817,607		19,859,770
Keller Group		—		4,863,988		23,843,093
Subtotal		135,883,119		150,224,649		171,091,451
Inter-segment Revenues:
NDX Laboratories		—		—		370,913
Green Dental Laboratory		40,445		117,242		199,525
Keller Group		—		—		160,384
Net Sales	$	135,842,674	$	150,107,407	$	170,360,629
Laboratory Operating Income:
NDX Laboratories	$	19,586,603	$	16,840,606	$	17,572,491
Green Dental Laboratory		3,571,803		4,820,007		4,665,630
Keller Group		—		446,151		3,228,640
	$	23,158,406	$	22,106,764	$	25,466,761
Total Assets:
NDX Laboratories	$	81,747,877	$	87,414,371	$	87,811,020
Green Dental Laboratory		26,889,263		26,537,905		26,756,893
Keller Group		—		24,848,553		25,769,930
Corporate		8,481,870		9,689,455		15,301,300
	$	117,119,010	$	148,490,284	$	155,639,143
Capital Expenditures:
NDX Laboratories	$	6,533,065	$	4,670,309	$	4,604,908
Green Dental Laboratory		86,529		350,299		463,763
Keller Group		—		45,073		756,581
Corporate		958,819		519,572		1,871,058
	$	7,578,413	$	5,585,253	$	7,696,310
Depreciation & Amortization on Property, Plant & Equipment:
NDX Laboratories	$	1,625,370	$	2,152,833	$	2,579,090
Green Dental Laboratory		205,183		271,476		330,820
Keller Group		—		98,433		452,935
Corporate		541,878		611,757		691,769
	$	2,372,431	$	3,134,499	$	4,054,614

F-27

NATIONAL DENTEX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Reconciliation of Laboratory Operating Income with reported Consolidated Operating Income:

	Year Ended		Year Ended		Year Ended
	December 31,		December 31,		December 31,
	2005		2006		2007
Laboratory Operating Income	$	23,158,406	$	22,106,764	$	25,466,761
Less:
Corporate Selling, General and Administrative Expenses		9,503,542		9,623,752		10,894,225
Amortization Expense — Intangible Assets		1,567,233		1,528,059		1,283,720
Add:
Other Expense		646,436		786,292		771,660
Consolidated Operating Income	$	12,734,067	$	11,741,245	$	14,060,476

F-28

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NATIONAL DENTEX CORPORATION

By:  /s/  DAVID L. BROWN

David L. Brown, President & CEO

March 12, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/  DAVID V. HARKINS David V. Harkins	Chairman of the Board and Director	March 12, 2008
/s/  JACK R. CROSBY Jack R. Crosby	Director	March 12, 2008
/s/  THOMAS E. CALLAHAN Thomas E. Callahan	Director	March 12, 2008
/s/  NORMAN F. STRATE Norman F. Strate	Director	March 12, 2008
/s/  JAMES E. MULVIHILL, D.M.D. James E. Mulvihill, D.M.D.	Director	March 12, 2008
/s/  DAVID L. BROWN David L. Brown	President, CEO, and Director (Principal Executive Officer)	March 12, 2008
/s/  WAYNE M. COLL Wayne M. Coll	Vice President & Chief Financial Officer (Principal Financial Officer)	March 12, 2008

EXHIBIT INDEX

Exhibit No.			Description of Exhibit
	3	.1(5)	Restated Articles of Organization of the Company, filed with the Massachusetts Secretary of State on October 14, 1993.
	3	.2(5)	Articles of Amendment, filed with the Massachusetts Secretary of the Commonwealth on September 26, 1995.
	3	.3(5)	By-Laws of the Company, as amended on December 31, 1982 and May 26, 1992.
	10	.1(3)*	Amended & Restated 2001 Stock Plan, as amended on May 16, 2006.
	10	.2(2)*	Change of Control Severance Agreement between the Company and David L. Brown, dated January 23, 2001.
	10	.3(2)*	Form of Change of Control Severance Agreements between the Company and each of Arthur Champagne, Richard G. Mariacher and Donald E. Merz dated January 23, 2001, and Lynn D. Dine dated May 1, 2004.
	10	.4(1)*	Employment Agreement between the Company and Donald E. Merz, dated November 1, 1983.
	10	.5(4)*	1992 Long-Term Incentive Plan, as amended.
	10	.6(4)*	Employment Agreement between the Company and Richard F. Becker, Jr., dated April 1, 1995.
	10	.7(4)*	Change of Control Severance Agreement between the Company and Richard F. Becker, Jr., dated April 1, 1995.
	10	.8(4)*	Employment Agreement between the Company and David L. Brown, dated April 1, 1995.
	10	.9(7)*	National Dentex Corporation Laboratory Incentive Compensation Plan, dated May 17, 2001.
	10	.10(7)*	National Dentex Corporation Key Employee and Corporate Support Group Incentive Compensation Plan.
	10	.11(7)*	National Dentex Corporation Employees’ Stock Purchase Plan, as amended effective April 4, 2000.
	10	.12(14)*	Second Amendment to National Dentex Corporation Employees’ Stock Purchase Plan.
	10	.13(11)	Second Amended and Restated Loan Agreement by and between Bank of America, N.A., National Dentex Corporation and Green Dental Laboratories, Inc. dated November 7, 2006.
	10	.14(7)*	National Dentex Supplemental Executive Retirement Plan.
	10	.15(7)*	National Dentex Supplemental Laboratory Executive Retirement Plan.
	10	.16(6)	Stock Purchase Agreement by and among John W. Green IV, Richard M. Nordskog and the Company dated as of March 1, 2005.
	10	.17(8)*	Form of Annual Director Fee Deferral and Restricted Stock/RSU Subscription Agreement.
	10	.18(8)*	Form of Restricted Stock Unit Agreement for Employees and Directors Under the Company’s Amended and Restated 2001 Stock Plan.
	10	.19(8)*	Form of Restricted Stock Agreement (Non-Employee Director).
	10	.20(9)*	Supplemental Executive Retirement Plan VI effective as of August 11, 2006.
	10	.21(10)*	Stock Purchase Agreement by and among William G. Keller, Thomas A. Keller and the Company dated October 5, 2006.
	10	.21(12)*	Amendment No. 1 to Supplemental Executive Retirement Plan dated as of January 17, 2006.
	10	.22(12)*	Amendment No. 2 to Supplemental Executive Retirement Plan dated as of January 17, 2006.
	10	.23(13)*	Written Summary of Compensation Arrangements with Richard F. Becker, Jr., Arthur B. Champagne, Wayne Coll and John W. Green effective January 24, 2007.
	10	.25*	Written Summary of Non-Employee Director Compensation Arrangements.
	10	.26(15)	Amendment dated October 24, 2007 to Second Amended and Restated Loan Agreement by and between Bank of America, N.A., National Dentex Corporation, and its subsidiaries listed therein.
	10	.27(16)	Loan Modification Agreement dated as of March 29, 2007 by and between Bank of America, N.A., National Dentex Corporation, Green Dental Laboratories, Inc., Keller Group, Inc., Keller Laboratories, Incorporation — Midwest, and Keller Laboratories, Incorporation — Southwest.
	10	.28(17)*	Retirement Agreement by and among National Dentex Corporation and Donald Merz dated January 2, 2008.

Exhibit No.			Description of Exhibit
	21	(18)	Subsidiaries of the Company.
	23		Consent of PricewaterhouseCoopers LLP.
	31	.1	Certification pursuant to Section 302 of the Sarbanes-Oxley Act (Chief Executive Officer).
	31	.2	Certification pursuant to Section 302 of the Sarbanes-Oxley Act (Chief Financial Officer).
	32	.1	Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act (Chief Executive Officer).
	32	.2	Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act (Chief Financial Officer).
Unless otherwise noted all exhibits are filed herewith.
* These exhibits relate to a management contract or to a compensatory plan or arrangement.

(1)	Incorporated by reference from the Form 10-K for the fiscal year ended December 31, 1999 as filed with the Commission on March 3, 2000.
(2)	Incorporated by reference from the Form 10-K for the fiscal year ended December 31, 2000 as filed with the Commission on March 13, 2001.
(3)	Incorporated by reference from the Proxy Statement filed on Schedule 14A with the Commission on March 29, 2006.
(4)	Incorporated by reference from the Form 10-K for the fiscal year ended December 31, 2003 as filed with the Commission on March 12, 2004.
(5)	Incorporated by reference from the Annual Report on Form 10-K for the fiscal year ended December 31, 2004 as filed with the Commission on May 24, 2005.
(6)	Incorporated by reference from the Current Report on Form 8-K/A as filed with the Commission on January 26, 2006.
(7)	Incorporated by reference from the Annual Report on Form 10-K for the fiscal year ended December 31, 2005 as filed with the Commission on March 16, 2006.
(8)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on May 22, 2006.
(9)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on August 14, 2006.
(10)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on October 6, 2006.
(11)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on November 8, 2006.
(12)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on December 12, 2006.
(13)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on January 29, 2007.
(14)	Incorporated by reference from the Registrant’s Registration Statement on Form S-8 as filed on November 16, 2008.
(15)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on October 30, 2007.
(16)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on April 2, 2007.
(17)	Incorporated by reference from the Current Report on Form 8-K as filed with the Commission on January 1, 2008.
(18)	Incorporated by reference from the Form 10-K for the fiscal year ended December 31, 2006 filed with the Commission on March 13, 2007.